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Abstract 
Biomedical sciences use a variety of data sources on drug molecules, genes, proteins, complete 
genomes sequences, diseases and scientific publications, etc. This system can be best pictured as a 
giant data-network linked together by physical, functional, logical and similarity relationships. A 
new hypothesis or discovery can be considered as a new link that can be deduced from the existing 
connections. For instance, interactions of two pharmacons – if not already known – represent a 
testable novel hypothesis. Such implicit effects are especially important in complex diseases such 
as cancer. Currently huge amount of data is generated by experiments, such as whole genome 
sequencing of metagenomic data. Deriving new information, i.e. linking the experiments to 
microorganisms and supporting the new hypothesis with known data requires the proper analysis 
of a data-network. 
The goal of the investigations carried out in this thesis is to predict novel drug combinations or 
novel biomarkers using the network of existing oncological and protein interaction databases and 
to interpret and analysis large metagenomic data using network principles. 
I showed that the overlap of network neighborhoods is strongly correlated with the pairwise 
interaction strength of two pharmacons used in cancer therapy, and it is also well correlated with 
clinical data. 
The strategy based on the hypothesis that novel, implicit links can be discovered between the 
network neighborhoods of data items lead to the discovery of novel biomarkers based on text 
analysis. In 2012 I prioritized ten potential biomarkers for ovarian cancers, two of which were in 
fact described as such in the subsequent years. 
I showed that applying network principles and fast aligners in the evaluation of metagenomic whole 
genome sequencing experiments could improve the classification performance, and even sensitive 
detection of pathogens is possible. 
The strategy seems to hold promises in several applications including prioritization of new drug 
combinations, discovering of novel biomarkers for experimental testing or sensitive detection of 
pathogens. Its use is naturally limited by the sparsity and the quality of experimental data; however, 
these aspects are expected to improve given the development of current databases. 
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1. Introduction 
The network view on biological data has profoundly influenced the ways we are looking 
at problems of diagnosis and therapy in life sciences today. In traditional paradigms, we used to 
look at data as isolated entities stored in organized databases. Today, we increasingly consider data 
as an interconnected network. There are many kinds of connections – for instance, drugs can be 
connected to diseases, to their protein targets, to genes producing the targets, or to drugs they can 
replace or antagonize. In a similar manner, proteins can be linked to other proteins they physically 
contact, to genes they regulate, to diseases they play a role in, etc. This is a very complex picture, 
because we have many types of entities and relationships that are defined in separate ontologies 
that in turn can be considered as networks of terms. The storage and manipulation of such a large 
body of data is clearly too demanding for current computers. In addition, such data networks are 
both incomplete and noisy. Namely, we have a seemingly large number of proteins, but the 
knowledge on proteins is rarely validated by experiment, and a large part of the annotations is just 
taken over from homologous proteins of various organisms. In addition, we cannot be sure whether 
two proteins are linked in all tissues and/or in all phases of the cell cycle. The solution of these 
problems is to break down the hypothetical data-network into specific - disease-specific, tissue-
specific, pathogen-specific, etc. - manually curated parts that contain reliable information on a 
given problem. This tedious and labor-intensive solution is justified only in very important fields. 
Cancer-specific data networks are an example of this approach. In addition, two major information 
sources can help data-sparsity problems. On the one hand, various high-throughput experimental 
methods (two hybrid systems, DNA sequencing, Chip-seq, etc.) provide novel kinds of molecular 
interaction data that in principle can be easily added to the existing databases. However, high 
throughput data are most often laden with noise, which has to be handled. In such cases, hierarchical 
data networks (i.e. ontologies) may offer a good framework to balance between the reduction of 
noise and sensitivity to discover novel data links from the experiments.  
On the other hand, literature databases that contain abstracts or full text of scientific papers 
provide a large body of new knowledge that can in principle be linked to molecular data. Again, 
the process is not trivial: scientific texts use natural language and concepts are often not analogous 
to the ones used in other texts or in molecular databases. 
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Disease-specific databases and tools represent a current approach where the above 
problems are tackled by large communities of scientists. Cancer databases and tools are a typical 
example, since cancer is one of the most important complex diseases which is responsible for ~15% 
of all human deaths, and which has >100 more-or-less well-characterized types and >500 human 
genes associated with it [2]. Oncologists use a variety of traditional databases, but there are a 
number of data-collection efforts dedicated to the gathering of data on various cancer types. All 
this provides a solid knowledge base for designing integrated data-networks in which novel 
questions related to cancer therapy can be answered.  
Here I am concerned with three types of questions that can be addressed via integrated data 
networks: i) finding drug combinations potentially useful for cancer therapy. I tackle this problem 
by using a simple network overlap measure applied to data networks; ii) finding novel gene-disease 
associations in ovarian cancer for generating a list of potential biomarkers. I approach this problem 
using a text mining approach applied to MEDLINE abstracts [3] as well as the STRING database 
[4]. iii) Finally, I present a practical application by testing a dedicated, data subnetwork in 
accelerating and improving the taxonomic identification. Here I take advantage of the fact that the 
taxonomic and even the functional subnetworks are hierarchical graphs, which allows a substantial 
speedup with respect to current algorithms. Section 1 is an introduction to the problem of biological 
topics discussed in this work, and it covers the mathematical and computational background as 
well. Section 2 presents the main database types used in this project. Section 3 describes the 
principle of hypothesis generation via network overlap analysis, the identification of drug 
combinations via a network overlap measure and the prediction of pathogenic species. Section 4 
discusses conclusions and future trends while summarizing the scientific results. 
1.1. Biological background 
1.1.1. Chemotherapy 
Chemotherapy is the most frequently used first-line treatment of cancer. Chemotherapeutic 
agents target all dividing cells in the body either by killing them (cytotoxic agents) or by blocking 
proliferation without cell elimination (cytostatic agents), regardless of their status as normal or 
neoplastic. Tumor cells proliferate rapidly, thus agents selectively damaging dividing cells exhibit 
a selective advantage. Victims of such a universal destruction are the fast-growing normal cells, 
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accounting for the side effects of chemotherapy such as damaged hair follicles, irritated epithelium 
of the mouth and digestive tract, and suppression of myelopoietic precursors in the bone marrow. 
Chemotherapeutic agents can be classified according to the mechanisms of their action. 
Drugs can destruct the structure of DNA, stop metabolic processes, and obstruct protein structures 
of the mitotic spindle. Cell cycle consists of four different phases: G1 (protein synthesis and cell 
growth), S (DNA replication), G2 (further protein synthesis and cell growth) and M (mitosis) – 
some agents are cell-cycle-phase-specific, while other agents require cell proliferation for action 
but are not linked to any given phases of the cell cycle [5]. Chemotherapeutic agents can be 
classified into five main categories.  
1) Alkylating agents are not cell-cycle-phase specific, and their effects are dose-dependent, thus 
cell killing is a linear function of the applied dose of the medication. They form covalent bond 
with amino, sulfhydryl, phosphate and carboxyl groups to alkylate biologically active 
molecules and block the function of DNA, but also RNA and proteins [5]. The group consists 
of nitrogen mustards, platinum agents, nitrosoureas and cyclophosphamides. Nitrogen 
mustards are similar to mustard gas and are mainly effective in the hematopoietic system [6], 
while the lipid soluble nitrosoureas used to target brain tumors penetrate through the blood-
brain barrier [5]. Carboplatin is a standard agent of care for ovarian cancer [7-9].  
2) Antitumor antibiotics have been isolated from natural sources, such as plants, bacteria and 
fungi. Antibiotics intercalate between DNA base pairs, thus inhibit transcription and RNA 
synthesis. Their effectiveness is limited by dose-dependent cardiotoxicity as a main adverse 
effect [10]. Frequently used antibiotics are actinomycin-D, mitoxantron, and anthracyclines 
such as doxorubicin. Anthracyclines also inhibit topoisomerases I and II.  
3) Antimetabolites are structurally similar analogues of naturally occurring molecules. They 
interfere with metabolic processes by either competing for key enzymes or substituting 
components of DNA during synthesis, thus block cell cycle in the S phase. Antimetabolites 
show a nonlinear dose-response, thus after a given concentration no further cells are 
eliminated. Methotrexate inhibits folate biosynthesis, ultimately leading to purine and 
pyrimidine depletion within the cell [11]. Nucleoside analog 5-fluorouracil and cytarabin 
interfere with pyrimidine synthesis, while mercaptopurin, azathioprine, pentostatin and 
thioguanin hamper purine production.  
DOI:10.15774/PPKE.ITK.2016.008
4 
4) Vinca alkaloids and taxanes consist of cell-cycle-phase specific antimicrotubule blocking 
chemotherapy agents. During the S phase vinca alkaloids bind to tubulin, prevent 
polymerization and eventually mitotic spindle formation. Taxanes on the other hand, such as 
paclitaxel and docetaxel, stabilize tubulin inhibiting depolymerization and cell division [12].  
5) Topoisomerase inhibitors, such as camptothecin analogs (irinotecan) inhibit DNA elongation 
by blocking topoisomerase I in the S phase of the cell cycle [13].  
Response to chemotherapy is classified as complete (tumor is untraceable), partial (50% 
shrinkage) or minimal (stable disease). When chemotherapy fails, tumor progression continues. 
Chemoresistance is a complex multifactorial phenomenon [14, 15]. Mechanisms of resistance 
include pharmacological factors such as inadequate drug concentrations due to low accessibility of 
the tumor. Cellular resistance factors include detoxifying or transport mechanisms reducing drug 
concentrations in the target cell, altered drug-target interactions including the ability of the cells to 
repair damaged DNA, tolerate stress and evade apoptotic death [16-20]. Inherited genetic 
variability also influences susceptibility to chemotherapeutic agents. Single nucleotide 
polymorphisms (SNPs) have also been linked to altered drug response [21]. The one-gene one-drug 
approach with relevance to cancer chemotherapy has been gradually replaced by studying genetic 
variation on entire biological or pharmacological pathways, such as the complex network 
underlying folate metabolism [22] or enzymes responsible for detoxification [23]. 
Combination chemotherapy blends cytotoxic drugs with different mechanisms of action. 
The goal is to eliminate a broader range of resistant cells in the heterogeneous population of 
cancerous cells, to prevent or slow the emergence of resistant clones, and to maximize the additive 
or synergistic effects of drugs on cell kill. Compelling evidence support combination treatments 
over sequential monotherapy [24]. Preferable combinations include drugs with different 
mechanisms of action, such as paclitaxel with cisplatin, and different pattern of resistance [5]. 
When applied sequentially, the order of combined agents influences responses. For example, 
carboplatin followed by docetaxel in advanced non-small-cell lung cancer patients suggested higher 
response rate when compared to reverse arrangements [25]. 
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1.1.2. Systemic therapy of recurrent or metastatic breast cancer 
In 2012 alone over 1.7 million women were diagnosed with breast cancer being the most 
common cancer in women [26]. High numbers pose economic burden and affect the quality of life 
of an enormous population. The universal goal to increase treatment efficiency is not trivial, as 
breast cancer is a heterogeneous disease. Based on molecular features breast cancers are grouped 
into subtypes with distinct gene expression pattern comprising luminal A, luminal B, basal like and 
HER2 positive subtypes [27]. Each of these phenotypes requires different management. The picture 
is further complicated with cancer stage and menopausal status. Local treatment of primary breast 
cancer differs from the systemic treatment of advanced or metastatic disease. Preoperative, so-
called “neo-adjuvant” treatments, such as anthracyclines or endocrine agents given preoperatively 
are expected to downstage the disease. Advanced incurable malignancies require a sturdier 
cytotoxic treatment compared to a less serious disease. The guidelines of the US National 
Comprehensive Cancer Network suggest a list of preferred single agents for recurrent or metastatic 
breast cancer (that is not HER2-positive): doxorubicin or pegylated liposomal doxorubicin, 
paclitaxel, capecitabine or gemcitabine, vinorelbin or eribulin. Other single agent chemotherapies 
include cyclophosphamide, carboplatin, docetaxel, albumin-bound paclitaxel, cisplatin, epirubicin, 
ixabepilone. Chemotherapy combinations are listed in Table 1.1 
Table 1.1. Chemotherapy combinations for recurrent or metastatic breast cancer 
adapted from the Guidelines of the US National Comprehensive Cancer 
Network 
Regimen1 Component 12 Component 22 Component 32 
CAF/FAC cyclophosphamide doxorubicin fluorouracil 
FEC fluorouracil epirubicin cyclophosphamide 
AC doxorubicin cyclophosphamide  
EC epirubicin cyclophosphamide  
CMF cyclophosphamide methotrexate fluorouracil 
NA3 docetaxel capecitabine  
GT gemcitabine paclitaxel  
NA3 gemcitabine carboplatin  
NA3 paclitaxel bevacizumab  
1The abbreviation of the given chemotherapeutic regimen (i.e. CAF/FAC is a drug combination 
consisting of cyclophosphamide, doxorubicin, fluorouracil etc.) 2Name of the component in the 
drug combination. 3Not available. 
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1.1.3. Targeted molecular therapy 
Unfolding the molecular mechanisms underlying neoplastic transformation [28] opened a 
new, “personalized” era in clinical practice. Identification of driver mutations [29] allowed the 
rational design of molecular-targeting agents (MTAs). MTAs as single or combination therapies 
aim at aberrations that appear in a broad range of cancers and can be targeted in many tumor cells 
simultaneously. Patients are eligible to a therapy with MTAs only if their cancer bears a driver 
mutation targeted by the given agent. Therapies include monoclonal antibodies (mAbs), that 
deplete growth factor supply for the cells or prevent receptor dimerization, and small-molecule 
inhibitors, that block the initiation of intracellular signal transduction or possess catalytic activities 
[30]. 
The efficacy of monotherapies using molecularly targeted agents is often inferior compared 
to combination strategies. The reason for this is that relatively few malignancies depend on only 
one unique pathway to achieve the malignant transformation. For instance, targeting the 
hyperactive ABL1 kinase with small molecule tyrosine kinase inhibitors, such as imatinib and 
nilotinib produced superior clinical outcome in chronic myeloid leukemia [31, 32]. The complexity 
of signaling pathways and the heterogeneity of tumors called forth the combination of MTAs and 
cytotoxic agents. In this, agents are selected based on biological considerations to alter 
complementary pathways of signal transduction or to inhibit multiple target molecules within the 
same pathway [33]. In general, MTAs are considered to be less toxic than conventional 
chemotherapies [34], but when combined, the crosstalk between pathways may result in 
unpredictable toxicities [35]. 
1.1.4. HER2 positive breast cancer 
Evolution of treatment choice in HER2-positive breast cancer illustrates the difficulties in 
targeting complex biological systems. About 20% of breast cancer patients overexpress Epidermal 
Growth Factor Receptor 2 (HER2), facing aggressive tumor growth and inferior prognosis [36]. 
The first successful targeted therapy approved by FDA in 1998 was an anti-HER2 monoclonal 
antibody, trastuzumab, combined with chemotherapy. The treatment dramatically changed the 
clinical outcome of the aggressive HER2-positive metastatic breast cancer [37, 38]. Trastuzumab 
monotherapy was effective in about 15-26% of patients [39], and combining trastuzumab with 
chemotherapy provided significantly better outcomes [40].  
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HER2 (ERBB2/neu) belongs to the family of type I receptor tyrosine kinases (RTKs) 
including EGFR (ERBB1), HER3 (ERBB3), and HER4 (ERBB4). HER2 is overexpressed in tumor 
tissue but not in healthy cells, hence offers an ideal target for personalized therapy. Ligand binding 
of RTKs – except HER2 with no known ligand - induces receptor homodimerization or 
heterodimerization at the plasma membrane. Dimerization activates complex signal transduction 
involving the PI3K/Akt, Ras/MAPK, and JAK/STAT pathways, leading to cell transformation and 
cancer. Ligand and heterodimer compositions tightly regulate downstream signaling. With its 
permanently open conformation, HER2 is a favored dimerization partner of the other RTKs 
conferring lateral transmission to create a complex network of signaling pathways [41].  
Redundant signaling cascades, as in the case of EGFR receptor family, facilitate bypassing 
the targeted node in the network [42]. Eventually, about 70% of patients develop resistance against 
trastuzumab. In addition, more superior patient stratification will be needed to improve initial 
clinical response. Despite constant evaluation of predictive biomarkers, the extent of HER2 
expression remains the sole reliable trait for treatment decision [43]. Improved outcome can be 
obtained in case the inhibition involves other members of the EGFR receptor family. Preferred first 
line treatment includes simultaneous treatment with pertuzumab and trastuzumab assisted either by 
docetaxel or by paclitaxel [44, 45]. Pertuzumab targets the second extracellular domain of HER2 
and prevents its dimerization with HER3.  
Following the most current NCCN guidelines, in case the preferred first line treatment 
cannot be implemented, the subsequent regimes should include the antibody-drug conjugate 
trastuzumab emtansine (T-DM1), consisting of trastuzumab covalently linked to a microtubule 
inhibitor [46]. Trastuzumab is also suggested to be utilized in combination either with paclitaxel 
and carboplatin, or with one of the following: docetaxel, vinorelbine, or capecitabine. Lapatinib, a 
small-molecule tyrosine kinase inhibitor blocks EGFR and prevents its dimerization with HER2. 
After trastuzumab failure, addition of lapatinib to chemotherapy improved post-progression free 
survival rates in metastatic breast cancer patients [47]. Trastuzumab combined with lapatinib offers 
a chemotherapy-free alternative to trastuzumab exposed HER2-positive breast cancer. 
Trastuzumab exposed HER2-positive breast cancer may also be treated with the combination of 
lapatinib and capecitabine, or trastuzumab and capecitabine. Trastuzumab can be combined with 
other single agents as long as anthracyclines are avoided due to increased cardiac cytotoxicity. 
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1.1.5. Ovarian cancer 
Ovarian cancer is the fifth most common cancer in women worldwide and the deadliest 
gynecologic malignancy, as less than 30% of patients with advanced disease reach 5-year survival 
[48]. It is characterized with extreme heterogeneity, as a considerable proportion of tumors does 
not originate from the ovaries [49, 50]. Their common features are their shared location and 
dissemination to the pelvic organs. Histological subtypes display cellular and molecular diversity 
and distinct pathogenesis. Type I tumors progress from benign precursor lesions and consist of low-
grade serous, low-grade endometrioid, clear cell, mucinous and Brenner carcinomas with a distinct 
genetic profile and a low malignant potential. Type II tumors including high-grade serous, high-
grade endometrioid, undifferentiated and mixed-mesodermal tumors are highly aggressive, 
genetically unstable, lack precursor lesions, frequently harbor p53 mutations (<90%), and 
approximately 20% of them carry BRCA1/2 mutations [51, 52].  
About 80-85% of women are diagnosed with serous carcinoma, followed by endometrioid 
(10%), with clear cell and mucinous cancers being the least common subtypes. Clear cell and 
mucinous tumors appear in earlier stages more frequently than serous cancers, providing a 
generally good prognosis. Type I patients fare better after surgery and usually do not require 
chemotherapy [53]. However, the lack of symptoms at an early stage frequently results in a late 
diagnosis when the tumor has already reached an advanced state. The extent of surgical tumor-
mass reduction is an important prognostic factor of survival. Complete resection of advanced 
tumors improves both progression-free and overall survival compared to suboptimal surgical 
outcomes [54]. Surgery complemented with adjuvant or neo-adjuvant carboplatin-paclitaxel 
treatment has been the standard of care in the past 15 years [55, 56]. In case of paclitaxel intolerance 
pegylated liposomal doxorubicin (PLD)-carboplatin or docetaxel-carboplatin treatments provide 
an alternative solution [57, 58]. Despite the good initial responses about 70% of patients relapse 
within the first three years. The relatively poor survival data compared to other types of solid tumors 
necessitated a more refined methodology. Ovarian histotypes are treated now as distinct diseases 
with different mutational profiles and treatment requirements, influencing early detection, clinical 
trial design and the identification of new drugable targets [59, 60]. 
Contrary to the good results associated with early stage mucinous cancers, women with 
advanced mucinous tumors do worse compared to other histological types of advanced disease 
related to the high frequency of platinum-resistance [61]. Mucinous tumors represent a distinct 
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spectrum of ovarian cancers ranging from benign to invasive with an individual molecular profile 
featuring frequent KRAS but infrequent p53 and BRCA mutations [62, 63]. Oxaliplatin combined 
with 5-fluorouracil represents a promising alternative treatment specific to mucinous tumors, 
validated in vitro and on xenografts [64]. 
Ovarian clear cell cancers (OCCC) in advanced stages are also particularly malignant, and 
refractory to platinum-based chemotherapy [65]. Clean cell cancers are characterized by high 
frequency mutations in the PIK3CA catalytic subunit of the PI3K gene [66] and mutations in the 
chromatin remodeling ARID1A gene [67]. The gene expression profiles resembling renal clean cell 
cancers, such as MET overexpression and overactivation of IL6-STAT3-HIF signaling pathway, 
suggest that antiangiogenic treatment used on renal clean cell tumors, such as the multi-kinase 
inhibitor sunitinib, may be applicable to OCCC [68].  
The high-grade serous ovarian cancer (HGSOC) is of particular interest, as it accounts for 
70-80% of ovarian cancer fatalities. Large portion of HGSOCs originate from outside of the 
ovaries, from the distal part of fallopian tubes [50]. Despite its sensitivity to platinum derived 
medications and other DNA damaging agents, patient survival has not been improved for years, as 
therapies targeting specific tumor biomarkers were lacking. Transcriptional profiling separated 
mesenchymal, immune, differentiated and proliferative subtypes associated with different 
prognosis, although the distinction has not yet been translated to clinical decisions [69]. Sequencing 
HGSOC revealed a frequent driver p53 missense or nonsense mutation indicating its role in tumor 
initiation [70], and the inactivation of tumor suppressor genes RB1, NF1, RAD51B, and PTEN 
[71]. CCNE1 encoding cyclin E1 for cell cycle progression is amplified in a large proportion of 
HGSOC that lacks defects in the HR pathways, likely representing an early event in tumor 
progression [51]. Drugs targeting cells deficient in DNA repair, such as poly (ADP) ribose 
polymerase (PARP)-inhibitors, selectively kill tumor cells with dysfunctional BRCA1/2. Olaparib, 
the first PARP-inhibitor have been approved for use as a maintenance therapy in Europe and for 
advanced recurrent disease in the USA, to the great advantage of BRCA-related ovarian cancer 
patients, particularly with a platinum-sensitive disease [72]. 
1.1.6. Future perspectives 
Precision medicine targeting specific mutations has its limitations and the transcriptional 
targets of key driver genes are still elusive [73]. The initial enthusiasm seems to dampen as long-
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term survival data have emerged with limited success. For example, initially well responding 
patients with cutaneous melanomas treated with the BRAF inhibitor vemurafenib relapsed shortly 
after treatment [74]. ALK-positive lung cancer patients treated with crizotinib showed a 65% 
response rate – but the median duration of response was only 8 months [75]. In HER2-positive 
breast cancer, the majority of patients develop resistance within the first year of trastuzumab 
treatment [76-78]. Current guidelines suggest the simultaneous combination of molecularly 
targeted and immune checkpoint therapy [79]. The concept behind this approach is that T cells of 
the adaptive immune system show a remarkable ability to match the diversity and adaptability of 
tumors. Immune therapy can unleash T cells specific to many antigens present in the tumor by 
targeting a single immune checkpoint. In spite of promising ongoing studies, current results suggest 
durable tumor [80] inactivation only in a fraction of patients. 
1.2. Metagenomics concepts 
Metagenomics is the genomic study of microbial communities, i.e. microbes coexisting in 
the same space and time. The term metagenome was coined to designate the genome content of the 
whole community. The study of these communities is as old as microbiology itself, since at the 
beginning it was not yet possible to separate microbial samples into taxonomic units, and later 
studies relied mostly on morphological features. Without going into details of this long and 
impressive development, one can concentrate on the current trends of metagenomic analysis today 
as summarized by a recent review of Escobar-Zepeda et al. [81]. First, sequencing technologies 
allow us to investigate the species as well as functional (gene) variety present in microbial samples. 
Species composition is easier to determine. We can analyze the 16S RNA genes of bacterial species 
according to the classical concept of Carl Woese. In this case, we can use amplicon sequencing of 
a short segment of bacterial genomes and compare it with 16S RNA databases. In this analysis, 
first step is assembling the whole sequence of the relatively short 16S RNAs present in the sample. 
This analysis gives an estimate of the known bacterial species present in a bacterial community and 
estimates unknown taxonomic units. 16S RNA analysis carries out a search in a collection of short 
sequences with sensitive alignment techniques, like BLAST [82]. This category is considered as 
the standard method, although it has its limitations. For instance, there is an essential need for PCR 
amplification, which comes with extra overhead and experimental bias. Word-based techniques 
and artificial intelligence may offer a solution by making it possible to build databases of clade-
specific recognizers this way facilitating the usage of rapid string matching techniques [83]. 
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Another approach is to use whole genome shotgun sequencing, i.e. a full-scale sequencing of the 
entire sample. Complete assembly of the reads into full genomes is not possible – there are simply 
too many species in the sample. Partial assembly of genome fragment is possible with current, high 
coverage sequencing and in-depth data processing, but the analysis is never complete. Instead, the 
individual sequencing reads are simply mapped onto the genome of known bacterial species, a 
technique known as binning. This analysis often gives more detailed species composition as 16S 
RNA sequencing, but it tends to be limited to microbial species with known genomes. There are 
two main categories of computational approaches addressing the above problem. The first one is 
the group of marker-based methods, which aims to overcome the difficulties by reducing the search 
space, namely by using small, specified datasets. MetaPhlAn applies a small database of clade-
specific sequence markers built from the genome sequences of the known taxa and then searching 
this with general-purpose aligners. Within large microbial communities, this kind of search can be 
exceptionally fast and accurate for identifying taxa and their approximate proportion. However, 
because of the fact that many strains often share identical markers, this approach many times lacks 
lower (e.g. strain-level) identification. This is a problem in the case of pathogenic strains of bacteria 
like E. coli. 
Taxon assignment [84], which is one of the most critical points for all approaches, is mainly 
achieved by different kind of lowest common ancestor searches in a taxonomic hierarchy. This 
means that the reads are assigned to one taxon (e.g. an E. coli strain), if possible, or to more than 
one taxon (e.g. 100% identity with an E. coli strain and an E. fergusoni strain), but in this case the 
lowest common taxonomic ancestor (the genus Escherichia) is reported. Numerous programs use 
this approach, like MEGAN [83, 85], Mothur [86] and SOrt-ITEMS [87]. 
The above-discussed tools represent a high variability in the computational approaches 
meaning that there is a demand for further improvements. For instance, current tools being 
developed for general purposes means that there is a need for specified tools. Furthermore, 
qualitative and quantitative answers cannot always be clearly separated: e.g., E. coli reads in an 
output may express the presence of it in the sample; however, the abundance of the species can not 
be measured by the number of identified reads. At this moment, only MetaPhlAn is able to supply 
reliable quantitative results for species abundance [88]. 
The third direction of metagenome analysis is directed towards the functional analysis of 
genes present in metagenomics samples. The principle is based on whole genome sequencing, but 
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the read to genome hits are evaluated in terms of gene groups, rather than in terms of strains and 
taxa. The analysis of gene function is based on the classification schemes such as COGSs 
(mentioned below). 
1.3. Networks in biology 
Biological databases, including the ones related to cancer therapy and metagenomics, 
contain annotated data items cross-referenced to each other. In the mathematical sense, such an 
entity can be pictured as a subgraph or subnetwork, in which some of the edges (cross references) 
point to other entities or subgraphs defined in other databases. For instance, a drug in the drug 
interaction database can be linked to another drug item within the same database, as well as to a 
disease defined in a medical ontology [89, 90], a protein defined in Uniprot, etc. In principle, there 
is no problem to represent all such subgraphs in one large network that we term here a data network. 
The advantage of such a network is that it allows a large variety of queries to be answered within 
the same system. In practice, the construction of such a large network is prohibitively difficult. First 
it would be far too large, second it would contain a large number of heterogeneous and partly 
conflicting data types [91]. The current solution is to build partial networks that allow one to answer 
a few questions related to a given project.  
From the practical point of view, cancer data networks consist of, on the one hand, 
dedicated cancer-related sequence databases, and on the other hand, molecular and molecular 
interaction databases that include drug and drug interaction databases. The former ones are 
collected by focused next generation sequencing projects carried out by an often large number of 
research groups (Table 1.2). Such projects contain data on cancer mutations, and are often divided 
into type-specific datasets or comprehensive datasets. Another subgroup of these databases are data 
resources that are made available via WWW interfaces and include dedicated search facilities. 
Molecular and molecular interaction databases used to build cancer data network consist 
of those datasets that help one to describe and interpret cancer-related sequence information. These 
databases can be roughly categorized as 1) general-purpose sequence databases, 2) drug-related 
databases, 3) molecular interaction databases and 4) literature databases. 
A wide range of experimental methods used to study molecular interactions fall into two 
broad categories: i) Traditional methods of molecular biology focus on functionally proven 
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interactions and try to gather fine details by studying the interacting partners with methods like x-
ray crystallography [92, 93], nuclear magnetic resonance [94, 95], often in conjunction with 
structural bioinformatics and/or conventional biochemical methods. Interaction data of a selected 
protein can be collected with methods such as affinity chromatography or co-immunoprecipitation 
[80, 96, 97]. These are typically “small-scale” (focusing only on very few molecules) and 
traditional biochemical methods. ii) Large-scale or system-level approaches can be used to collect 
a large number of interaction data in one experiment. One of the best known methods for detecting 
protein-protein interactions is the yeast two-hybrid system [98]. The underlying idea is that the 
expression of the reporter genes depends on two separate components, a binding domain (BD) and 
an activation domain (AD). If the two domains are indirectly connected via a protein-protein 
interaction, where one of the interaction partner is fused with BD and the other fused to the AD, 
then one can detect the reporter gene. This approach makes it possible to detect a large number of 
interactions by screening a certain protein against a DNA library representing all possible proteins 
the organism can have. Another system-level technique, proteomics, can be used to study post-
translational modifications or protein-protein interactions via affinity purification coupled with 
mass spectrometry (AP-MS). This approach can also be useful for detecting strong connection 
between proteins, thus exploring protein complexes [99]. High-throughput methods are productive 
but there are several drawbacks and biases – among others, the number of erroneous interaction 
assignments can exceed 10 percent. 
In addition to experimental methods, the body of databases available in other fields is also 
a source of information. While experiments provide data on the biological entities themselves, the 
databases provide information on a wide variety of concepts. In this way we broaden the scope of 
molecular interaction data to “data networks” that allow us to link biological data to the results of 
further scientific fields. For instance, a drug database such as Drugbank [100] provides information 
on chemical structures and their biological targets (proteins and genes) and/or the diseases. A 
database of scientific publications, on the other hand, provides information on a large class of 
descriptions (scientific abstracts) that are linked to each other by common keywords, authors, 
statements etc. Further examples for special data network are the ontologies. These are special, 
hierarchical knowledge representations; for example, the Anatomical Therapeutic Chemical 
Classification (ATC) System classifies drugs into groups at five levels in a hierarchical way. Thus 
the classification system can be seen as a simple ontology, more specifically a forest (disjoint union 
of trees). The roots of the individual trees are the first level characters/classes of the ATC system 
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and the leaves are the full ATC codes (7 characters). There are 14 main groups at this level such as 
code A (Alimentary tract and metabolism), code B (Blood and blood forming organs), 
General-purpose databases such as Uniprot [101], Ensemble [102] or RefSeq [103, 104], 
GenBank [105] hold high quality and reliable information about proteins and genes (focusing on 
the amino acid or nucleotide sequence, protein names or descriptions, and citation information). 
Usually they provide data mining tools and APIs as well. 
Drugbank database [100] is one of the most comprehensive and freely available, complex 
data source about drugs. Currently, it holds information about 2200 FDA approved and more than 
6000 experimental drugs. It also provides detailed information about the food-drug and drug-drug 
interaction information. The information was manually curated from web resources and published 
papers and has been continuously developed [106, 107]. It also provides data about drug 
mechanism of action and drug labels and ADMET (drug metabolism, absorption, distribution, 
metabolism, excretion and toxicity) profile, thus the drug card of Drugbank could be a rich source 
of text mining. 
TTD database [108] is tailored to peptide molecules and its target information. It also 
includes information about diseases and drug combinations, however the last one is only available 
as excel tables, but not in a structured format, such as XML. Both Drugbank and TTD contains 
manually curated data. 
STICH [109-111] is an automatically created, integrated database. It was created by using 
similar concepts as those of the STRING network. The database focuses on small molecules and 
their relations to other small molecules and proteins. Similarly to the STRING database there are 
various types of associations between the molecular entities. It mainly contains protein-chemical 
and chemical-chemical links based on text mining and other complex predictions extended with 
chemical structure description strings. 
The Drug Combination Database [112, 113] focuses on agents combined together to 
achieve some therapeutically advantage over single agent drugs. Drug regimens are typically used 
in treating cancer and other complex diseases. The database is partly based on the FDA orange 
book [114], clinical trials (https://clinicaltrials.gov/), and publications. It also holds information 
about the individual drug components, such as ATC codes, target and cross references. 
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Furthermore, it also provides annotations for drug combinations, such as possible mechanism of 
actions, interaction type, suggested doses, etc. 
Drug side effects and drug interactions are often not covered in standard public databases. 
These kinds of data are available, for instance, in the SIDER database [115, 116], where the side 
effects are extracted from the drug labels (using controlled vocabulary such as UMLS [90]). A 
well-maintained collection of drug side effects is provided by the Tatonetti Lab [117]. 
Experimental results of protein-protein interaction measurements are deposited in various 
primary databases such as the Database of Interacting Proteins (DIP) [118], Biomolecular 
Interaction Network Database (BIND) [119], Molecular Interactions Database (MINT) [120-123], 
Biological General Repository for Interaction Datasets (BioGRID), Human Protein Reference 
Database (HPRD), IntAct Molecular Interaction Database [124]. 
The DIP database contains large number of manually curated and reviewed interactions 
from numerous species [118, 125]. It also provides some services and visualization tools for the 
available data [126], and a cytoscape plugin (MiSink) [127]. Different evidences for the interactions 
were integrated and considered manually. 
Human Protein Reference Database (HPRD) [128] contains various types of data about 
proteins such as post-translational modification, known or predicted disease associations, cellular 
localization, tissue expression, mainly from publications. The data have also been reviewed by 
scientific experts. The database contains information about 30047 proteins and 41327 interactions 
among them. 
Another important protein-protein interaction database is IntAct [124, 129-131], developed 
and maintained by the European Bioinformatics Institute (EBI), updated on regular basis. The 
interactions were partly curated from literature (14074 publication) in collaboration with the Swiss-
Prot team, or the data were submitted directly. They also use controlled vocabularies [132] (PSI-
MI [133, 134], gene ontology [135] and NCBI taxonomy terms [136]) for annotating the 
interactions and the proteins. The database contains information about the interacting domains as 
well. 
The information about the interactions is dispersed among different databases. Sometimes, 
these databases were curated/reviewed redundantly, so it is a natural need to make a standard data 
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representation and data integration. The MiNTAct [137], Imex [138], Mentha [139] consortial 
databases integrate the molecular interaction data collected from 11 databases. 
STRING (Search Tool for the Retrieval of Interacting Genes) is one of the largest 
integrated protein interaction databases, which covers 66.9 Mio predicted and known interactions 
between proteins of 1100 organisms. The majority of the interactions (44.1 Mio) are predictions. 
The links between the proteins are some kind of associations (among them several indirect ones) - 
not only physical interactions. The evidence types for the associations are neighborhood, gene 
fusion, co-occurrence, co-expression, experiments, databases, text mining, and homology. Each 
type of association has a confidence score, which is a probabilistic measure of the reliability of the 
link. The several types of links and their confidences can be combined into one association with 
one confidence score. 
Transcription factor databases contain sequence motifs and genomic locations collected 
from genomic data using bioinformatics methods. In the network representation of the database the 
nodes are DNA motifs linked to genomic locations. A typical example of transcription factor 
databases is Transfac, first published by Edgar Wingender’s group in 1994 [140]. The database is 
manually and continuously updated. The current release contains 7915 sites assigned to 6133 
transcription factors. Further examples of this database are given in Table 1.2. 
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Table 1.2. Cancer-related databases and resources 
Database Description URL Refs. 
Comprehensive databases and resources 
TCGA The Cancer Genome Atlas http://cancergenome.nih.gov/ [141] 
CGP Cancer Genome Project 
http://www.sanger.ac.uk/research/projects
/cancergenome/ 
[142] 
CPTAC 
Clinical Proteomic Tumor 
Analysis Consortium 
http://proteomics.cancer.gov/programs/cp
tacnetwork 
[143, 
144] 
ICGC 
International Cancer 
Genome Consortium 
https://www.icgc.org/ [145] 
Data mining resources 
COSMICMart BioMart tool for COSMIC https://cancer.sanger.ac.uk/cosmic/login [146] 
IntOGen 
BioMart 
BioMart tool for IntOGen http://biomart.intogen.org/ [147] 
UCSC Cancer 
Genomics 
Browser 
A visualization and analysis 
tool specialized to cancer 
data 
https://genome-cancer.ucsc.edu/ 
[148, 
149] 
ICPS 
An Integrative Cancer 
Profiler System 
http://server.bioicps.org/ [143] 
NCG 4.0 Network of Cancer Genes http://ncg.kcl.ac.uk/ 
[150, 
151] 
CGWB 
The Cancer Genome 
WorkBench 
http://cgap.nci.nih.gov/cgap.html [152] 
CancerMA 
A web-based tool for 
analyzing microarray data  
http://www.cancerma.org.uk/information.
html 
[153] 
ICPS 
An Integrative  
Cancer  
Profiler System 
http://server.bioicps.org/ [143] 
Databases of genetic variations in cancer  
COSMIC 
Catalogue of Somatic 
Mutations in Cancer 
http://cancer.sanger.ac.uk/cancergenome/proj
ects/cosmic/ 
[154] 
CaSNP Cancer SNP data on CNAs http://cistrome.dfci.harvard.edu/CaSNP/ [155] 
DriverDB 
Cancer driver genes and 
mutation database 
http://driverdb.ym.edu.tw/DriverDB/intranet/
init.do 
[156] 
IntOGen Integrative Oncogenomics http://www.intogen.org/ [157] 
MoKCa 
Mutations, Oncogenes, 
Knowledge & Cancer 
http://strubiol.icr.ac.uk/extra/mokca/ [158] 
CGAP 
Cancer Genome Anatomy 
Project 
http://cgap.nci.nih.gov/ [159] 
Mitelman 
Database 
Database of chromosome 
aberrations and gene fusions 
in cancer 
http://cgap.nci.nih.gov/Chromosomes/Mitel
man 
[160] 
CGC 
The Cancer Gene  
Census 
http://cancer.sanger.ac.uk/cancergenome/
projects/census/ 
[161] 
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Table 1.2. (Continued) 
Databases of epigenetic, proteomic and transcriptome variations in cancer 
CanProVar 
Human Cancer Proteome 
Variation Database 
http://bioinfo.vanderbilt.edu/canprovar/ [162] 
MethyCancer 
A database of human 
DNA methylation and 
cancer 
http://methycancer.psych.ac.cn/ [163] 
CellLineNavigator 
Expression profiles of 
cancer cell lines 
http://www.medicalgenomics.org/celllinenavig
ator/ 
[164] 
ITTACA 
Integrated Tumor 
Transcriptome Array and 
Clinical data Analysis 
http://bioinfo.curie.fr/ittaca [147] 
PubMeth 
Cancer methylation 
database based on text-
mining of PubMed 
http://matrix.ugent.be/pubmeth/ [165] 
OncomiRDB 
A database of 
experimentally verified 
oncomiRs 
http://bioinfo.au.tsinghua.edu.cn/member/jgu/o
ncomirdb/ 
[166] 
Cancer-specific clinical and drug resources 
CancerDR 
Cancer Drug Resistance 
Database 
http://crdd.osdd.net/raghava/cancerdr/ [167] 
HPtaa 
The Human Potential 
Tumor Associated 
Antigen database 
http://www.bioinfo.org.cn/hptaa/ [168]  
CancerResource 
A resource of cancer-
relevant compound and 
protein interactions 
http://bioinf-data.charite.de/cancerresource/ [169] 
CanGEM Cancer Genome Mine http://www.cangem.org/ [170] 
DTP 
Anti-cancer agent 
database 
http://dtp.nci.nih.gov/docs/cancer/searches/standa
rd_mechanism.html 
[171, 
172] 
ITTACA 
Integrated Tumor 
Transcriptome Array 
and Clinical data 
Analysis 
http://bioinfo.curie.fr/ittaca [147] 
Cancer-type-specific resources and databases 
RCDB RCDB 
http://www.juit.ac.in/attachments/jsr/rcdb/homen
ew.html 
[173] 
curatedOvarianData 
Clinically annotated 
data for the ovarian 
cancer transcriptome 
http://bcb.dfci.harvard.edu/ovariancancer/ [174] 
PED 
Pancreatic Expression 
Database 
http://www.pancreasexpression.org/ [175] 
HLungDB 
Human Lung Cancer 
Database 
http://www.megabionet.org/bio/hlung/ [176] 
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Special types of molecular interactions are metabolic and signal transduction molecular 
interactions. One of the oldest pathway databases is KEGG [177]. However, the current version 
holds information related to pathways such as genome, diseases and related drugs. It provides a 
global map for each pathway. 
Reactome [178], similarly to KEGG, is a comprehensive, manually curated, high quality 
pathway database with support of enrichment analysis and data visualization. 
The Human Metabolome Database [179], however, concentrates on small molecule 
metabolites, and it is a rich source of biomarker discovery. It also provides enzymatic, biochemical, 
and clinical data. 
The signaling and metabolic pathways are often handled as separate entities, however, 
crosstalks and regulatory coupling exist between the pathways [180]. The Signalink [181] and 
NDEx databases [182] not only offer manually curated and reviewed pathway information, but 
provide more context for pathway analysis such as transcriptional and post-transcriptional 
regulators. 
Scientific literature databases contain data collected from scientific journals using 
increasingly automated electronic submission links. Medline/Pubmed [183] is perhaps the best 
known representative of public scientific literature databases, it collects scientific abstracts from 
the publishers and provides them with a unified system of keywords (mesh terms, reference [184]). 
In the network representation of the database, the nodes are scientific abstracts; the edges 
correspond to shared keywords, citation links (X cites Y), etc. The Medline database was first 
published in 1971 and it gained a very wide acceptance as it became available via the PubMed 
search facility in 1997. For machine learning purposes, the database is downloaded, and word 
combinations are identified via natural language processing techniques in order to create new index 
tables. Further examples of this database are given in Table 1.3. 
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Table 1.3. Representative examples of molecular and molecular interaction databases 
relevant to cancer therapy 
 
 Contents URL Ref. 
1. General-purpose databases 
Uniprot 
Comprehensive 
database of protein 
sequences 
http://www.uniprot.org/ [101] 
RefSeq Genome sequences 
http://www.ncbi.nlm.nih.gov/projects/geno
me/assembly/grc/ 
[185] 
GenBank 
Comprehensive 
database of genetic 
sequences 
http://www.ncbi.nlm.nih.gov/genbank/ [105] 
Ensemble 
Comprehensive 
database of sequences 
with data mining tools 
http://www.ensembl.org/index.html [102] 
2. Drug-related databases 
DrugBank 
Drug data and drug-
drug interactions 
http://www.drugbank.ca/ [100] 
Therapeutic 
Target Database 
(TTD) 
Therapeutic Target 
Database 
http://bidd.nus.edu.sg/group/cjttd/TTD_HOM
E.asp 
[108] 
STITCH 
Drug molecular 
interactions 
http://stitch.embl.de/ [109] 
DCDB 
Drug Combination 
Database 
http://www.cls.zju.edu.cn/dcdb/ [186] 
Offsides, 
TwoSides 
Drug adverse effects 
and Drug-Drug 
Interactions 
http://tatonettilab.org/resources/tatonetti-
stm.html 
[117] 
Drugs.com 
FDA approved drugs 
linked to diseases and 
target proteins/genes 
www.drugs.com  
SIDER Drug adverse effects http://sideeffects.embl.de/ [115] 
3. Protein /protein interaction databases 
DIP 
Experimentally and 
manually validated 
molecular interactions 
http://dip.doe-mbi.ucla.edu/dip/Main.cgi [118] 
HPRD (Human 
Protein Reference 
Database) 
Experimentally and 
manually validated 
molecular interactions 
http://www.hprd.org/ [128] 
Intact 
Manually curated 
molecular interaction 
http://www.ebi.ac.uk/intact/ [124] 
MIntAct 
Manually curated 
integrated database 
http://www.ebi.ac.uk/intact [137] 
STRING 
Protein/protein 
interactions as well as 
connections derived 
from other databases 
http://string-db.org/ [187] 
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Table 1.3. (Continued) 
4. Transcription factor databases 
TRANSFAC 
Transcription factors 
and binding sites 
http://www.gene-
regulation.com/pub/databases.html 
[140] 
JASPAR 
Transcription factor 
binding profile 
database 
http://jaspar.genereg.net/ [188] 
DBD 
Transcription factor 
prediction database 
http://www.transcriptionfactor.org/ [189] 
5. Metabolic pathways 
KEGG 
Kyoto 
Encyclopedia of 
Genes and 
Genomes 
http://www.genome.jp/kegg/ [177] 
Reactome 
Curated pathway 
database 
http://www.reactome.org/ [178] 
MetaCyc 
Metabolic pathway 
database 
http://metacyc.org/ [190] 
HMDB 
Human 
Metabolome 
Database 
http://www.hmdb.ca/ [179] 
6. Signal transduction databases 
NetPath 
Manually curated 
signal transduction 
pathways 
http://www.netpath.org/ [191] 
Signalink 
Manually curated 
signal transduction 
pathways 
http://signalink.org/ [181] 
NDEx 
Integrated network 
database 
http://www.ndexbio.org [182] 
7. Mutation databases 
COSMIC 
Somatic mutations 
found in human 
cancer 
http://cancer.sanger.ac.uk/cosmic [192] 
OMIM 
Disease gene and 
mutation database 
of humans 
http://www.omim.org/  [193] 
8. Literature databases 
PubMed/Medline PubMed/Medline http://www.ncbi.nlm.nih.gov/pubmed [194] 
EMBASE 
Biomedical and 
pharmacological 
bibliographic 
database 
http://store.elsevier.com/embase  
Scopus 
Bibliographic 
database of peer-
reviewed literature 
http://www.scopus.com/  
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1.4. From databases to data networks 
One way to picture data network construction is to take a database of cancer genes or 
proteins, and then cross-reference it to general-purpose sequence databases, drug-related databases, 
etc. that will form a network among various types of entities allowing the cross querying of diverse 
biological databases in a unified manner. In practice, the construction of such a large network is 
prohibitively difficult, partly because of the incompatibility of ontologies, partly because of the 
sheer size of the network [91]. The design of these data networks is largely facilitated by database 
frameworks capable to handle an arbitrary set of biological entities and relationships [195]. 
Physical or structural connections rely on the well-known fact that molecules practically never 
function alone but rather in association with other molecules such as ligands, lipids, amino acids, 
proteins and nucleic acids. On the one hand, there are structural associations between the elements 
that can be “strong” such as covalent bonding and tight associations in the cytoskeleton 
(microfilaments are polymers of G-actin proteins), or “transient” such as in the case of receptor-
ligand associations. Understanding the nature and the type of these relationships is crucial for 
interpreting complex biological phenomena such as disease mechanisms. As an example, the active 
forms of proteins are most often complexes assembled from various types of other proteins or other 
types of molecules such as RNA, DNA or small molecules. On the other hand, there are functional 
associations, such as between members of signaling pathways, transcriptional or metabolic 
networks. Functional associations may not even involve structural interactions, for instance distant 
members of a metabolic pathway are functionally related. The common motif in these widely 
different scenarios are the links between molecules that can involve various structural and 
functional aspects. For instance, a transient interaction act in catalyzing sequential steps within a 
metabolic network, or in a signaling pathway such as modifying the protein by adding phosphate 
group, etc. 
Biological databases, including the above examples, contain annotated data items cross-
referenced to each other. In the mathematical sense, such an entity can be pictured as a subgraph 
or subnetwork, in which some of the edges (cross-references) point to other entities or subgraphs 
defined in other databases. For instance, a drug in the drug interaction database can be linked to 
another drug item within the same database, as well as to a disease defined in a medical ontology, 
a protein defined in Uniprot, etc. In principle, there is no problem to represent all such subgraphs 
in one large network, which we term here a data network – but such a network would be 
prohibitively complicated for practical uses. One of the solutions is warehousing, wherein 
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databases are stored as parallel items within the same computer, and integrated concepts and new 
data types take care of appropriate matching of underlying entities and attributes, including the 
resolution of conflicts. The result of such a common representation can be best pictured as a 
network of data, where the original data items (say drugs, target proteins, diseases, mutations) are 
represented in a common large network. For instance, a network combining drug targets and 
protein-protein interactions will contain links (network paths) between proteins that are targeted by 
the same (or similar) drugs, or drugs acting on proteins that are in physical contacts. In such a data 
network all data items (say drugs, target proteins, diseases, and mutations) are connected via a 
variety of different links, which makes processing complicated and time-consuming. As a practical 
workaround, one can construct a dedicated database tailored to a specific task, and that can be 
queried with simpler tools [195]. 
From the practical point of view, it is useful to distinguish comprehensive resources that 
aim to cover, for instance, all known genes and proteins and one selected type of interaction (say, 
regulatory connections). On the other hand, specialized resources concentrate on a selected species 
(Homo sapiens), or on a selected tissue type, or on a selected mechanism (signal transduction, or 
protein kinases). A few representative examples of databases are listed in Table 1.2. 
1.5. Graph – definitions and notations 
From the logical point of view, all interaction networks and data networks are graphs in 
which nodes are entities, such as molecules, diseases, i.e. biological, physical, as well as conceptual 
objects, while the edges or links between nodes are relationships, such as molecular interactions, 
drug-disease connections, drug compatibilities, etc. 
A graph or network can be defined by a set of vertices and a set of edges. Two vertices are 
connected if they are linked to each other. For example, let the nodes be the cities and the edges be 
the roads. In this structure, there is an edge between two vertices if two cities are connected directly 
by a road. The graphs can be grouped by their different properties, such as weighted or unweighted 
edges, or by degree distribution, etc. [196]. 
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The network is an ordered set of vertices and edges, ( , )G V E , where V  is the set of 
vertices and E  denotes the set of edges. The two sets define the graph. In this paper the nodes are 
denoted by their indices (i.e. k , kv  or kx ). 
There are several simple properties and classification of graphs.  
The degree of a node kv  is the number of edges being incident to the node and it is denoted 
by deg( )kv . 
Indegree is the number of incoming edges; outdegree is the number of edges that leave the 
vertex (outgoing links). If we consider an undirected weighted graph, then the degree of a node will 
be the sum of the weight of incident edges.  
If a number (a weight) is associated to the edges, we talk about weighted graph. The weight 
might mean cost or the strength of the chemical association between two molecules, lengths, etc. 
In our example, the weight can be the length of the road between two settlements.  
Let x , y be two nodes of a graph ,x y V , and ( , )e x y  the edge between node x , y ,
( , )e x y E . The graph is undirected if ( , )e x y  has no orientation. For example, if there is a road 
from city A to city B, it means that we can travel from A to B and B to A as well, there is no 
distinction. On the other hand, if ( , )e x y does have orientation, then the graph is directed. If 
( , )e x y E  it does not necessarily implicate that ( , )e x y E  is true. 
Path of length l  is an ordered collection of l  vertices 
1 2( , , , )lv v v V  and 1l   edges
1 2 2 3 1( ( , ), ( , ), , ( , ) )l le v v e v v e v v E  . The distance of two nodes is the minimal number of edges 
traversed on a path between iv  and jv . If there does not exist a path between the two elements, the 
distance is infinite. The shortest path between iv  and jv  is the minimum number of traversed edges:
 min ( , ) | , 1,2,i il v v i j V . 
A graph is connected if and only if there exists a path between any two distinct vertices in 
the graph. If the graph is not connected, then it consists of smaller independent components.  
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A directed graph is strongly connected if exists a path between any pairs of nodes 
considering the orientation of the edges. 
For practical uses, a graph is often represented as an adjacency matrix. It describes which 
nodes are connected and which are not. The adjacency matrix A  is an N N  matrix, where N V : 
 1 vertex  and are  adjacent0 otherwisei jij v va   (1) 
If the graph is weighted, then the entries of matrix A represent the weights of the edges. If 
the graph is undirected, then the matrix becomes symmetric. 
The Laplacian matrix of a graph is often called admittance matrix and it is often used. The 
Laplacian matrix is an N N  matrix: 
 deg( ) if 
1 if  vertex  and are  adjacent
0 otherwise
i
ij i j
v i j
L i j v v
 
  

 (2) 
The Laplacian matrix can be formulated by the matrices: 
 L D A   (3) 
Where D  is a diagonal matrix and A  is the adjacency matrix of the graph. 
 
1 2( , , , )ND diag d d d , (4) 
where
N
i ijj
d A . If the graph is directed then the id  elements are the outdegrees of the node. 
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1.6. Network analysis techniques 
A great large number of mathematical and algorithmical approaches exists for gaining 
insight knowledge of a network. Each of them give us an information from different perspectives. 
The global descriptors usually give us information about the network itself, while the different 
cluster analysis techniques reveal the substructures inherently existing in a network. A large 
number of algorithms has been developed for exploit the complex relationship existing between 
nodes or set of nodes in a network. This work is concerned with the concept of network 
neighborhood that cat can be defined as a subnetwork or subgraph around a selected node. Defining 
a subnetwork in a data-network can be carried out either by i) static or ii) dynamic methods.  
i) Static methods use the data network “as is”, and simply omit those data that do not fulfill 
some criteria. For instance, we omit those data types and connection types that do not belong to the 
subnetwork. In this way, we can define tissue-specific networks, or we can define the neighborhood 
of a gene as nodes and edges that are less than n  steps away within the network, using paths that 
contain only a given set of edges. For instance, a neighborhood of a potentially affected drug can 
be defined as a set of genes that are in the same metabolic or signaling pathway as the known drug 
target.  
ii) Another, probabilistic way is to define a subnetwork as an effect that propagates from a 
central node, such as a drug target. This is a dynamic approach since the nodes of the network get 
weighted in an iterative fashion during propagation, and at the end, one can select those nodes that 
have weights exceeding some threshold value. We are concerned with two kinds of propagation 
algorithms used in several fields of computer science, PageRank [197-199] and diffusion [200-
203]. 
1.6.1. Random walk based algorithm: PageRank 
This algorithm is a special case of random walk on data network: a walker starts at a certain 
data node, and then randomly selects the next node from its neighbor, then moves there, and so on. 
In the case of PageRank, the walker not only selects a neighboring node randomly, but also, it can 
move to any other nodes with a certain probability (“restart probability”). If the walker is only 
allowed to move to a specific set of nodes or to the neighboring nodes, then this is the PageRank 
with prior algorithm [198, 199, 204]. If there is prior knowledge available about which nodes are 
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more relevant, then one can use this information to bias the original PageRank scores. For example, 
known drug targets, known diseases can be used as prior knowledge; in that case, the walker 
initiated from these specific data nodes, and in every iteration it goes back, restarts with a certain 
probability.  
More formally, first, we define the prior probabilities as pr , and then we use this 
information in the random walk in the following way: 
 ( )
1
1
( ) (1 ) ( , ) ( ) ( )
ind v
i i
u
P v p u v P v pr v 

 
   
 
  (5) 
( )iP v  denotes the personalized PageRank score at iteration step i , ,u v V  and ( , )p u v  is the 
probability of traveling from node u  to node v .   is the "restart probability" ( 0 1   ).   is 
the probability that we restart the random walk, meaning that we go to the starting nodes according 
to the prior probability distribution, thus biasing the results towards to the initial conditions. If 
( ) 1pr v N v V   , then ( )iP v  is the original PageRank score at iteration step i .  
It is possible to reformulate the PageRank iteration in matrix form: 
 1 (1 )i T iP M P pr     , (6) 
where M is the probability transition matrix that can be generated from the adjacency matrix of G. 
Let  denote the diagonal matrix defined in equation 4, then simply: 
  M DA   
 
(7) 
Note that M  is not necessary symmetric even if A  is. 
Other well-known algorithms based on random walks include k-step Markov [204], HITS 
[205], HITS with Prior [204]. 
D
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1.6.2. Random walk and kernel methods 
Random walk based methods are also used to quantify the similarities between nodes, 
however it is not a trivial question how we can measure the relatedness (or similarity) between the 
network nodes. There are several ways to deal with this: for example, by counting all possible paths 
between any pair of nodes, or by considering a diffusion process on the graph, which resembles to 
the random walk on graph. The connection between diffusion and random walk has been well 
established.  
The kernel methods offer a very good framework for quantifying the similarities [202]. 
They also offer a wide range of powerful algorithms for all kind of problems of pattern analysis, 
for example for clustering, classifications, rankings, principal component analysis, correlations, 
and regression problems. Furthermore, kernel-based algorithms can be used on general types of 
data, such as sequences, text documents, sets of points, vectors, images, graphs, etc. by leveraging 
the typical properties of such type of data. Kernel methods use the following (theoretic) working 
flow: The first step is mapping the data to high or infinite dimension space, called feature space. In 
the feature space, each coordinate of the transformed input vector is a feature of the data. In the 
second step, we apply our algorithm in this new space in order to find relations between the data. 
The mapping function is not necessarily linear; it is possible to use wide scale of nonlinear 
functions. Kernel methods compute the inner product between all pairs of data vectors from the 
feature space. This approach proves to be very efficient, because it is computationally cheaper than 
finding the exact feature vectors for all data points, and plenty of algorithms can operate using only 
the scalar product. One of the most famous examples is Support Vector Machines (SVM), but there 
are kernel based algorithms for Fisher’s linear discriminant analysis (LDA), principal components 
analysis (PCA), canonical correlation analysis, ridge regression, and for spectral clustering [202]. 
A kernel is a function :k X X   that for all ,x z X  satisfies:  
 ( , ) ( ), ( )k x z x z   , (8) 
where X is the input vector space, and   is the mapping function from X to a feature space F . 
 : ( )x x F    (9) 
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There are typical kernel and mapping functions, one of them is the following: let nX   
 2( , ) ,k x z x z  (10) 
This k kernel function corresponds to the following mapping function: 
 2
, 1: ( ) ( )
n n
i j i jx x x x      (11) 
If the kernel function and some input vectors are given, then one forms a matrix that is 
called kernel matrix or Gram matrix. The elements come from the evaluated kernel function on all 
pairs of data points and the matrix has the following properties: 
I. Symmetry: The kernel matrices are always symmetric:  
 ( , ) ( ), ( ) ( ), ( ) ( , )k x z z x x z k z x        
(12) 
II. Gram matrix: Given a set of vectors  1, , nS x x  the Gram matrix G is an n n  
where ,ij i jg x x  If we evaluate the k kernel function on the input data with the 
corresponding mapping function , we get a Gram matrix:  
 ( ), ( ) ( , )ij i j i jg x x k x x     
(13) 
III. Kernel matrices are positive semidefinite matrices. A symmetric matrix is positive 
semi-definite if its eigenvalues are all non-negative. This holds if and only if  
 0Tv Av   (14) 
1.6.3. Kernels on graph 
Kernels can be applied on several types of structured data, such as graphs, strings, trees, 
etc. These kernels allow us to study the graph structure and they can reveal important features, such 

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as the similarities between nodes or clusters. If node x  is linked to node y , and node y  is linked to
z , it is reasonable to say that x  is similar to z , although there may not exist any direct link between 
them. Diffusion kernels quantify the similarities between two nodes by considering all possible 
paths between them. It is a reasonable consideration that longer paths have a lower contribution to 
the similarity than the shorter ones. Depending on the type of the discount factor applied on the 
path length one can define various different graph kernel types [202]. The path counting is 
indirectly carried out by powering the adjacency matrix. 
Kondor and Lafferty introduced the exponential diffusion kernel [206] as ( edK ): 
 
1
exp( )
!
k k
ed
i
A
K A
k




  , (15) 
where the discount rate is exponential. Parameter   regulates the decay of the longer path. 
Another slower discount rate leads to another type of kernel, called von Neumann diffusion 
kernel [201], defined by the following formula: 
 
1
1
( )k kND
i
K A I A



   , (16) 
which only exists if the 
1
2
A

  Where 
2
A  is the spectral norm of A . 
It is easy to see that these kernels are well defined since they are positive semi definite and 
symmetric because of the construction process. The exponential diffusion kernel and the von 
Neumann diffusion kernel have the same eigenvector as the adjacency matrix, the only difference 
is that how they reweight the eigenvalues of A . 
The exponential function is always positive, therefore the rescaled eigenvalues are positive 
as well, thus the exponential diffusion kernel is positive definite. In the case of von Neumann 
diffusion kernel, the rescaled eigenvalues are
1(1 )  , thus this kernel is also positive semi 
definite. 
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T. Ito showed that kernels give us a unified framework for the importance and relatedness 
[200]. At first sight, one can say that the importance measure is different from the similarity 
measure since importance is defined on a node while similarity is defined between nodes. Let 
( , )G V E  be a weighted (all weight is positive) connected undirected graph and A  the 
corresponding adjacency matrix and v  an importance score vector of G . For example, v  could be 
the dominant eigenvector of A , and it is well known that the entries of v  are the scores of how 
important a node is [197, 200, 205]. Let us consider the Tvv  matrix. The i th row (or column) gives 
a ranking, which is identical to the one defined by v . 
Let   be the dominant eigenvalue of A , if it has multiplicity one, then:  
 1
lim( )n T
n
A vv

  (17) 
It is also proved that:  
 
1
1
lim
n
k k T
k
A vv
 



 
 
 
 
  (18) 
It has a consequence in the case of von Neumann kernel, if we choose   as
1
  
, then the i
th row (or column) of NDK  
gives the same ranking as the HITS ranking. The parameter   can be 
interpreted as bias towards the ranking based on importance. If we choose a small , then the 
importance of the node is not really dominant. However, if 0   then the importance has an effect 
on the similarity defined between the nodes, thus von Neumann kernel offers a framework to study 
the similarities and the importance together. 
The Laplacian exponential diffusion kernel ledK  is almost the same as the edK . The 
difference is that instead of adjacency matrix we use minus Laplacian matrix in the formula. This 
can be interpreted as a heat diffusion on the graph. Diffusion is a physical metaphor used to model 
transport phenomena on networks. In our case, we assign an imaginary quantity, such as “energy” 
or “drug action” to one node of the network – for instance the gene targeted by the drug – and then 
use an iterative process to compute how this quantity diffuses along the network. Let ix  be the 
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quantity of the energy on node. It diffuses to the neighboring nodes with rate 
ija , so we can write 
that the energy of node i  is increased by 
1
N
ji jj
a x t
  between a small time interval t . The energy 
loss of the node is: 
1
N
ij ii
a x t
 . It leads to the following differential equation for ( )x t : 
 ( )
( )
dx t
Lx t
dt
   (19) 
The solution of this differential equation with respect to the initial condition (0)x  is: 
 ( ) (0)Ltx t e x , (20) 
In a similar way to PageRank with prior, it is possible to incorporate prior knowledge about 
the data network, i.e. relevant drugs to a disease by regularizing the Laplacian matrix [200]. The 
regularization could be interpreted as alteration of diffusion process by i.) controlling (increasing 
or decreasing) the energy loss of a node, ii.) altering (increase or decrease) the input energy flow 
on certain edges, iii,) both of the above. All of the above alterations can be described with different 
regularization parameters, more formally the regularized Laplacian matrix defined as: 
 
,L QD WAW     (21) 
Where the W and Q matrices are defined as follows: 
 if  and x (0) 0
1 if  and x (0) 0
0 if 
i
ij i
i j
w i j
i j
  
  

 (22) 
 
0
0
if  and x 0
1 if  and x 0
0 if 
i
i
ij
i j
q i j
i j
  

  

 (23) 
Where ,t   and   are the regularization parameters of the algorithm.  
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The evaluation of an extremely large system of ordinary differential equations could be a 
challenging task; however, using sparse linear algebra and leveraging the sparseness of a typical 
data network, the solution could be computed in reasonable time. Instead of focusing on computing 
the matrix exponential, one could focus on the approximation of the matrix-vector product gaining 
a significant speed up. The expression (0)Lte x  could be approximated using iterative methods 
such as Arnoldi algorithm [207-209].  
There are more graph kernels and variations such as commute time kernel [210], that is the 
Moore-Penrose pseudo inverse of the Laplacian matrix. F. Fouss [210] also showed in his paper 
that the average commute times and the average first passage times of the random walk can be 
computed using the kernel. 
1.6.4. Methods for graph kernel computation 
Computing a kernel matrix of an extremely large graph is a computationally expensive task 
(the time complexity is , where  is the number of nodes in the graph). The above presented 
graph kernels can be classified into two groups, one is kernels based on von Neumann series, and 
the others are kernels based on matrix exponential. It is well known that computing the inverse or 
matrix exponential of a general, large matrix is a computationally challenging problem. The size 
of a human protein-protein interaction network is approximately 20000 x 20000 (this is considered 
to be large). Since the computational time is considerable, finding the optimal kernel parameters 
for an application has also become challenging. To overcome this limitation, approximation 
algorithm can be used, such as Arnoldi algorithm [209], or Cholesky decomposition [211]. Further 
advantage of that algorithms is that they exploit the graph sparsity, which is an inherent property 
of the biological networks [212]. 
It is a frequent case in practice, that not the whole kernel matrix is needed, but the product 
of the kernel with a vector, and in that case, Arnoldi algorithm can be extremely useful for 
computing that product [207, 209, 213].  
The computation of von Neumann series is also possible using series approximation, 
however the approximation speed does greatly depend on the condition number of the adjacency 
or the Laplacian matrix, which is typically very high in biological networks like STRING [4], thus 
the convergence is slow. The other approaches are based on the matrix decomposition, like 
)( 3nO n
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Cholesky decomposition technique [211]. Although, this decomposition technique approach is 
“direct”, thus it does not leverage the sparsity property directly, it is still possible to reduce 
computation time by transforming the adjacency matrix by using the reverse Cuthill–McKee 
algorithm [214]. 
1.6.4.1. Krylov space methods 
The evaluation of matrix functions, such as matrix exponential or inverse, is often 
challenging in practice. In a number of such cases, Krylov subspace methods are easily applicable, 
especially in the time evolution of a complex system, but we can use them in several other fields, 
such as solving linear equations, finding the eigenvalues of a matrix, and evaluation of square root 
or trigonometric functions [205].  
Let matrix be large and sparse. Then Krylov space methods are useful, especially if we 
want to evaluate the following matrix vector product: 
 ( ) , where ,N N Nf A b A b   
:  is a function for which ( ) is definedf D f A   
(24) 
    
In most applications, only the product ( )f A b , and not ( )f A  is needed. For example, when 
we solve the linear equation Ax b , the solution is 1A b , thus the solution is the result of the 
multiplication of the inverse matrix with b . Another example of solving a system of ordinary 
differential equations given: 
( )
( )
dx t
Ax t
dt
 , and (0)x  as the initial condition. Then the solution is
( ) (0)Atx t e x . In that case, the solution is also a vector, given by a matrix vector product. 
Krylov space algorithms are iterative methods, and they give an approximation of the 
solution with an acceptable error within a reasonable computational time. They have some further 
advantages over other iterative methods, namely the matrix A  is required only for computing matrix 
vector products. It is a very advantageous property while working with large sparse matrices. 
Usually, the computation cost of a matrix vector product is ( )O N N , but it is easy to construct 
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data structures and procedures, for which the cost of evaluating of Ab  is only ( )O N , where   
is the number of nonzero elements per row. Another important benefit is that the approximation of 
( )f A b  for a smooth function f ( f is continuously differentiable, such as the exponential 
function) converges super linearly [207].  
The family of Krylov space methods has many members. The Generalized minimal 
residual method (GMRES) [215], Conjugate gradient method (CGN) [216], Biconjugate gradient 
method (BiCG) [217] solve linear equation (you can decide whether your matrix is hermitian or 
not). Based on Arnoldi and Lánczos algorithm, it is possible to find the extreme eigenvalues of A  
as well.  
1.6.4.2. Arnoldi algorithm 
Most of the Krylov space methods are based on the outcome of the Arnoldi algorithm. The 
main idea is to project matrix A  to a smaller space, called Krylov subspace, and looking for a 
solution in this smaller space. Arnoldi algorithm computes the projection of A , and builds an 
orthogonal basis on the Krylov subspace, and this projection can be seen as the compressed version 
of A [209]. 
Krylov subspace is a vector space spanned by the vectors of Krylov sequence,
 s
K  which 
is a set of vectors generated by A  and b : 
  2 1, , , , msK b Ab A b A b   (22) 
The m th Krylov subspace of 
N NA   and 0, Nb b   is:  
    2 1 1, , , , ( ) :mm mK span b Ab A b A b q A b q P      (23) 
mP  
are the polynomials with degree m . If A  is sparse, we can generate sK  very easily 
since in every iteration we just multiply A  with the result vector of the previous iterations.  
The approximation of the matrix function ( )f A b  with the help of Krylov space is done by 
looking for a polynom [209]:  
 1( ) ( )mf A b p A b  , (24) 
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where 
N NA  , v  is a nonzero vector and 1mp   
is a polynomial with degree m-1. The 
approximation is also the element of the Krylov subspace ( mK ). The goal is to find an element in 
mK  that approximates ( )f A b . 
The Arnoldi approximation of ( )f A b  is defined by [209]:  
 
1( ) , where =m m mf Q f H e b    (25) 
The rationality behind this approximation is that mH  represents the compression of A  into 
( , )mK A b  with respect to the basis mQ  and 1mb Q e , where me  denotes the m th unit coordinate 
vector. The matrix values of mQ  and, mH  as calculated by a modified Gramm-Schmidt process 
[209] that generates a m  orthonormal vectors in mK . 
1.6.4.3. Approximating the matrix exponential 
The exponential of a matrix plays an important role in many applications such as in the 
analysis of networks. Although formula 25 computes a matrix vector product, it is possible to get 
the full exp( )A  column by column. One gets back the i th column of Ae  by choosing b  as
 i
e , 
where 
N N
ie
  and ie  is the unit coordinate vector. The approximation formula for i th column 
of matrix exponential of A  is: 
 1
mH
i me e Q e u
   , (26) 
where 1u  also denotes the unit coordinate vector, but the dimension of 1u  is m  ( 1
mu  ). First, 
we compute the first column, then the second column, and so on. 
1.6.5. Ranking in networks 
In bioinformatics, many problems are related to rankings. A typical example in 
bioinformatics is protein annotation, where an unknown protein is queried against a large and 
comprehensive protein database with a proper aligner such as BLAST. The output is a ranked list 
of proteins in the database, where the top hits are the most similar proteins to the query. These top 
lists might be the basis of the next step in the research. But not only the sequences are usually 
subjected to ranking, but all sorts of biological entities, such as drugs, drug combinations, pathways, 
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mutations, peptides, nodes in network, etc. The questions is naturally arising: how to define ranking 
on networks.  
Ranking of nodes can be the representative of importance within a network, or in other 
cases, it can indicate how close the node is to our query representing our basic knowledge on the 
subject. That type of knowledge can vary depending on the field of application, for example in the 
case of drug repositioning, the most important knowledge is about the known applications of that 
drug, or in the case of the disease candidate gene prioritization, the input is the known genes related 
to the disease.  
We assume that graph G  is connected, and the adjacency matrix of the graph ( )A G  has 
dimension N N . The prior knoweldge is represented as vector denoted by 0p  with dimension 
1N  . and also have a vector with dimension N  denoted by 0p . 
1.6.5.1. Ranking by using PageRank with priors 
This algorithm is very similar to the k-step Markov in a sense that this is also an iterative 
algorithm and we get probability distribution in every iteration step what we can use for ranking or 
prioritization. But this also converges to a steady state distribution, which is not equal to the original 
PageRank vector, since it is biased towards an initial distribution, which is our prior knowledge 
about the system. Using prior knowledge as the initial distribution of the random walk ( 0p  and 0p  
also normalized to : 01 ( ) 1
N
i
p i

 ), a probability distribution is generated in every step ( denoted 
by 
( )kp ), which can be seen as a ranking vector. The i th entry of 
( )kp  will be the score of node i . 
This will be the probability of being at this node after k  step with respect to the initial condition 
and the restart parameter
   as described in Section 1.6.1. The higher probability means higher 
rank. This is similar to the relative importance of a node. In the case of PageRank, the pr  in 
equation 6 will be replaced by 0p  . 
1.6.5.2. Ranking based on kernels 
The entries of the kernels can be considered as the similarity between a pair of nodes. Here 
one can simply reweight the prior knowledge vector with the proper kernel values. In the case of 
the exponential diffusion kernels (exponential diffusion kernel, Laplacian exponential diffusion 
kernel, regularized Laplacian exponential diffusion kernel), we choose the diffusion and the 
1
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regularization parameters as we want (of course they have to be positive number). On the other 
hand, when we work with von Neumann diffusion kernel, Laplacian diffusion kernel, or with the 
regularized Laplacian kernel, we have to choose the diffusion parameter ( ) carefully, otherwise 
the convergence of the series is not guaranteed. The
max
1
0 

  , where max  is the spectral norm 
of matrix A  (or L , depending on which kernel we investigate). Let K be a kernel matrix, and the 
query vector be 0p , then the ranking p  is simply defined as : 
 0p Kp   (27) 
There are other ways of using kernels. Since the entries are inner products, it is easy to 
derive distance measure from the kernel. Another question is whether we have to normalize the 
kernel or not. The normalization here means that the norm of the vectors in the feature space is one. 
1.6.5.3. Measuring ranking performance 
A common question in bioinformatics is that how good a ranking is [1, 218]. In such cases, 
the traditional ROC (receiver operating characteristic) analysis [1] could be useful, since the 
ranking can be seen as a classification task. The various indices derived from the ROC curve, such 
as AUC (Area Under ROC Curve), precision, recall are particularly useful for characterizing the 
performance.  
The original use of ROC analysis is related to binary classification tasks, where the goal is 
to tag an element either as positive (+) or as negative (-). The classification algorithm is generally 
trained on elements with known class (training set). Usually, a testing phase follows the training 
process in order to assess the performance of the classification algorithm with respect to a given 
parameter set. The test set is distinct from the training set, and its label is also known (+ or -).  
The algorithm classifies each element in the element test set as either positive or negative. 
If the element is positive and is classified as positive, then this is a true positive (TP) hit, if it is 
classified as negative then this is a false negative hit (FN); on the other hand, if an object is negative 
and mapped as positive it is called false positive (FP), if it is classified as negative, then this is a 
true negative hit (TN). The classification result is then summarised in a so-called contingency table 
that contains the counts of TP, FP, TN, FNs. Then various indices could be derived from the 
contingency table, such as accuracy, sensitivity, F-measure, etc. For ROC analysis, the false 
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positive rate (FPR) calculated as: FP FP TN  and the true positive rate (TPR) calculated as: 
TP FN TP  are particularly important.  
In many cases, the classification is not binary, i.e. the classifier assigns a score instead of 
a label to each object representing the “certainty” of the membership to a class. In that case, the 
result is a ranking defined on the score. The classifier is considered good if the positive examples 
are ranked in the top of the list, while the negatives are ranked in the bottom of the list. The 
classification is poor if the positive elements are uniformly distributed in the ranked list. Following 
this guideline. one can transform non-binary classification into a binary classification by applying 
a threshold value, where the objects having a larger score are considered as positives and the other 
objects as negative. After the thresholding step, one can build a contingency table and derive the 
corresponding TPR, FPR values. In the final step, the ROC curve is created from the TPR and FPR 
values by applying various threshold values on the ranking. Sonego et al. used the below figure 
(Figure 1.1) to illustrate the process. 
After the construction of the ROC curve, the AUC value could be calculated. This is 1 if 
the ranking is perfect (all positive elements are ranked at the top), and 0.5 if the classification is 
random. 
1.6.6. Inference in ontologies 
Ontologies, often represented as directed acyclic graphs (DAG) or trees, are special 
networks capable of expressing hierarchical biological knowledge. The practical graph mining of 
that special structures often require other approaches than simple random walk or diffusion due to 
the hierarchy. Typical examples for hierarchical structures are gene ontology (GO) [135], disease 
ontology (DO) [89], clusters of ortholog groups (COG), taxonomy, etc. 
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The similarity between two or more nodes in the hierarchy is usually characterized through 
their lowest common ancestor. The similarity value is calculated based on a property of one of the 
common ancestors, such as information content (IC), or the shared path, or distance, or the 
combination of the above. The IC quantifies the specificity of a node at a given level. The IC of a 
node ( x ) is the negative log likelihood of the probability of the node ( )p x  being used. These can 
be estimated from the annotation frequencies. Resnik measure [219] is one of the most commonly 
used semantic similarity measures [220, 221], that is the most informative common ancestor 
(MICA) of two nodes: 
     , IC ,i j i jsim x x MICA x x   (27) 
In many cases the data nodes (ontology terms) are assigned to various entities, such as 
proteins and drugs; usually, the cardinality of such a relationship is many to many. If the goal is to 
Figure 1.1. Constructing a ROC curve from ranked data (taken from Sonego et al. 
[1]) 
The TP, TN, FP and FN values are determined compared to a moving threshold; an example is shown 
by an arrow in the ranked list (left). Above the threshold, + data items are TP, - data items are FP. 
Therefore, a threshold of 0.6 produces the point FPR = 0.1, TPR = 0.7, as shown in inset B. The plot is 
produced by moving the threshold through the entire range. Data were randomly generated based on 
the distributions shown in inset A [1].  
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quantify the similarity between the entities and not between the terms, then two types of approach 
could be used, one that discards the structure of ontology, the other is aggregating all similarity 
between the terms annotated to the entities. The former reduces the ontology knowledge into a 
presence absence vector ( ig ), where the i th entry is 1 if the i th term is annotated to the entity, 0 
otherwise. In the final step, the similarity between the entities is computed with the help of a 
standard vector similarity or distance measure, such as Jaccard, cosine or Hamming distance. The 
cosine similarities between two drugs (or any other type of entities) can be computed as: 
  , 1
T
i j
GO i j
i j
g g
S D D
g g
    (28) 
The score is 1.00 if the two entities have the completely same term annotation and 0 if they do not 
share any term. 
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2. Databases and methods 
Many tools, pipelines, IDEs, libraries, technologies and programming languages have been utilized 
throughout the projects as well as a large body of datasets. During the development I used a desktop 
computer with Intel(R) Core(TM) i5 CPU (3.33GHz) and 16GB RAM as well as a DELL 
PowerEdge R720 server equipped with 2 Intel(R) Xeon(R) CPU E5-2640 (2.50GHz) processors 
and 32 GB RAM.  
2.1. Databases 
The protein-protein interaction data were taken from the STRING database [222] 
(http://string.embl.de/, retrieved on 28th august of 2012). I also used an archived version of STRING 
database, release version 6.3 (in use from December 12, 2005 to January 15, 2007) for hypothesis 
testing. The drug related data (drug targets, synonyms, aliases, ATC codes) were taken from the 
Drugbank [106] via the JBioWH [195] (https://code.google.com/p/jbiowh/, retrieved on 12th 
September of 2012), STITCH [110] (http://stitch.embl.de/, retrieved on 4th September of 2012) and 
TTD [223] (http://bidd.nus.edu.sg/group/TTD/ttd.asp, retrieved on 23th July of 2012) databases. 
The drug interaction data were taken from http://drugs.com/ (retrieved on 11th November of 2013). 
The drug combination data were taken from the DCDB [186] (http://www.cls.zju.edu.cn/dcdb/, 4th 
March of 2012), and TTD [223] (http://bidd.nus.edu.sg/group/TTD/ttd.asp, retrieved on 23th July 
of 2012) databases. 
From the STRING database, the human protein-protein associations and their combined 
confidence scores were used. From the STITCH database only those drug-protein associations were 
considered which had i) experimental evidence or ii) database evidence with at least 0.800 
confidence, and the overall confidence was at least 0.900. Molecules such as Na+, Ca2+, ATP, etc., 
that had more than 45 targets were excluded from the dataset. All filtering algorithms were 
implemented in MATLAB R2014a. 
Published clinical trial data on trastuzumab were collected from the ClinicalTrials database 
(www.clinicaltrials.gov) using the word ‘trastuzumab’ in pairwise combination with all the 43 
chemotherapeutic agents approved for breast cancer (amsacrine, azacitidine, bleomycin, 
cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cladribine, cyclophosphamide, 
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cytarabine, dacarbazine, daunorubicin, daunorubicin <liposomal>, docetaxel, doxorubicin, 
epirubicin, estramustine, etoposide, fludarabine, fluorouracil, gemcitabine. idarubicin, ifosfamid, 
irinotecan, ixabepilone, lomustine, mercaptopurine, methotrexate, mitomycin-c, mitoxantrone, 
nelarabine, oxaliplatin, paclitaxel, pemetrexed, pentostatin, temozolomide, teniposide, thioguanine, 
topotecan, vinblastine, vincristine, vinorelbine) on the 1st of January 2013. ClinicalTrials.gov is 
developed by the U.S National Institute of Health and contains summary information about clinical 
studies conducted all over the world. Only 18 agents were studied in combination with trastuzumab 
in 81 trials. The findings were narrowed down to trials in which the effect of the combined therapy 
was studied (n=43). For trials in which trastuzumab was studied in combination with more than 
one agent, these duplicates were included only once. Only the data recorded according to Response 
Evaluation Criteria In Solid Tumors Criteria (RECIST) [224] were used. Overall clinical response 
(rate) (OR) was calculated from percentage of patients with complete response (CR) and partial 
response (PR) (OR = CR + PR ) [224]. The Confirmed Clinical Benefit (CCB) was calculated from 
CR, PR, and stable disease (CCB = CR + PR + SD) [224]. Finally, the median progression free 
survival (PFS) and the median overall survival (OS) data were added in months. 
2.2. Data preprocessing 
The data networks have been stored in traditional relational databases. In my projects I 
used MySQL and Oracle based systems. For designing the entity-relationship (ER) diagrams I 
partly used the Oracle SQL Developer program (http://www.oracle.com/technetwork/developer-
tools/sql-developer/) and the MySQL Workbench Tool 
(http://www.mysql.com/products/workbench/). 
The DCDB was integrated with Drugbank, TTD, STRING, STITCH and JBioWH data, 
and the necessary constraints and indices were built. The various types of ambiguities have been 
handled manually. The programs accessed the databases through JDBC (Java Database 
Connectivity).  
The STRING, DrugBank and STITCH databases were preprocessed (filtered to human 
related proteins and chemicals as described above) in Java and later in Python using dedicated 
parsers written for that purpose. All the protein ids were mapped to UniProtKB accession numbers, 
using the mapping files provided by the UniProt (idmapping tool).  
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The programs also transform the data into necessary format to make the data import into 
the database easier.  
Although the Oracle DBMS supports XML and has advanced retrieval and indexing 
utilities, I implemented a dedicated parser for Drugbank in Python, because it is more simple to 
integrate the information via dedicated data structures. For that purpose I used 
xml.etree.ElementTree module (https://docs.python.org/3/library/xml.etree.elementtree.html). 
The data was loaded into the database either with the Oracle SQL Developer migration tool 
or with the SQL*Loader utility.  
The document sets in our experiments were acquired from the MEDLINE database through 
its PubMed system [194] using the Entrez Programming Utilities [225] via Biopython [226]. Each 
document set consisted of citations that comprised of abstracts obtained from PubMed by executing 
boolean queries. The target sets of texts were restricted to abstracts of articles, because unlike the 
majority of full texts, they are freely available online in XML format. 
The sequence databases used in our experiments were created from indexed blast database 
files. The raw indexed files were retrieved from the ftp site of the NCBI along with the NCBI 
taxonomy and the corresponding GI (genbank identifier) - ncbi taxon id mapping. In my 
experiments I used the NT database as the main sequence source. The raw sequence database was 
stored in fasta format. During the second step of database preprocessing the nt database was split 
into ~4Gb pieces and the header of each sequence was replaced by the GI identifier and the taxon 
id of the organism. Then the database was indexed by the Bowtie2-build program. Since the original 
NT database contains all types of sequences from various organisms, not only microorganisms, it 
is reasonable to create subsets (i.e. only bacteria, only bacteria and virus etc.). Such precalculated 
databases are available at https://code.google.com/p/taxoner/wiki/07_Databases. The 
preprocessing steps were implemented via UNIX shell scripts in Python and in C. 
2.3. Methods: programs and environments 
The network neighborhood analysis was carried out in the Matlab programming environment. The 
data networks have been stored in dedicated MATLAB data structures using object-oriented 
programming features. The raw data loaded from the database via JDBC and SQL queries. The 
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queries describe the filtering process, i.e. which type of interactions should be included and which 
not. In my experiment the weight of the edges between the proteins were the confidence values 
provided by the STRING database. The weight of drug-protein and drug-drug connections has been 
universally 1. In my application all types of drug – protein associations were considered to be a 
link (i. e. proteins/genes targeted by drug, enzymes, carriers).  The network object furthermore 
holds information about itself and can compute various network properties: i.e. finding the 
connected components, calculates the degree distribution, regularized Laplacian matrix, 
corresponding probability transition matrix, (see equation 7 for details). It also contains the proper 
id mappings and annotations. The network itself is represented as a simple sparse matrix. It is 
necessary to filter the data network to the largest connected component, otherwise the numeral 
stability cannot be guaranteed. In the case of large, undirected networks (number of nodes > 15000), 
the largest connected component was calculated via heuristics that use the small world property. 
Basically, I started a random walk from the node with the largest degree (likely to be in the largest 
connected component) and I continued the iteration until all nodes had been found in the 
component. It is implemented as a simple matrix-vector multiplication, where the vector is updated 
in every iteration, in which non-zero entry implies that the node is indeed in the component. On the 
other cases the graphconncomp() function is used. Generally, as much data as possible was pre-
calculated and stored in matlab binary format. The data network, kernel matrices, random 
distributions, different drug-drug interaction scores have been stored and they were loaded on 
demand.  It is reasonably, since many times the same data is required and it is computationally 
much cheaper to store and retrieve the data then compute on demand. The execution time of such 
calculations heavily depends on the size of the data network. In our case (human related database) 
it requires 6-24 hours on an average desktop computer. The Gene Ontology was retrieved via the 
Bioinformatics Toolbox™ of MATLAB.  
./taxoner -dbPath path/to/database/fasta/ -taxpath 
/path/to/nodes/nodes.dmp -seq 
/path/to/fastq/illumina.fastq -p 6 -o Results/ -dbNames 
bacteria;archaea 
The Taxoner uses other type of network approaches. The algorithm was implemented in ANSI C, 
since C is suitable for building computationally demanding programs. The program is only running 
in GNU/LINUX environment. In order to harness the advantages of many core architectures the 
POSIX Thread and MPICH third party libraries were used for support parallelism. The first step in 
the pipeline is aligning the reads against the reference genomes using the bowtie2 program with the 
provided or default parameters. Since the database may consist of several pieces, such as in the 
DOI:10.15774/PPKE.ITK.2016.008
46 
case of nt, each read has to be mapped to the sequences in each sub-database. After all mappings 
are calculated the taxonomic binning is started. For each hit in a SAM file the LCA is calculated 
and reported. In the end the various temporary output files are merged with help of the UNIX sort 
command and the final LCA, alignment information of the best hit is reported. Optionally, it is 
possible to generate a MEGAN compatible report.  
For usage in large-scale pipelines, Taxoner can be run from the command line. An example is: 
./taxoner -dbPath path/to/database/fasta/ -taxpath 
/path/to/nodes/nodes.dmp -seq /path/to/fastq/illumina.fastq 
-p 6 -o Results/ 
where the -dbPath tells Taxoner where to find the sub-databases (and Bowtie2 indexes), the -
taxpath is the path to the NCBI nodes.dmp file, the -seq is the input fastq reads, -p specifies the 
number of threads and -o is the output folder for the results. As an alternative, where the user wants 
to align reads to only a part of the database (say all the bacteria and archaea), an extra parameter -
dbNames can be added, with a semicolon separated list of prefixes for each database subset: 
./taxoner -dbPath path/to/database/fasta/ -taxpath 
/path/to/nodes/nodes.dmp -seq 
/path/to/fastq/illumina.fastq -p 6 -o Results/ -dbNames 
bacteria;archaea 
The running time was measured in a UNIX environment using shell scripts. Each measurement 
was repeated at least 3 times, then the average value was reported. The NCBI taxonomy was used 
as reference taxonomy. In order to compare the results of MetaPhlAn with Taxoner’s, MetaPhlAn’s 
taxonomy was mapped to the NCBI taxonomy, thus each marker and clade received a unique NCBI 
taxon id. The ambiguities were resolved manually (as many as 22), however. these clades were not 
related to my datasets. MEGAN was set to use the same taxonomy as Taxoner. The Taxonomy tree 
module was implemented in Python in order to assess the necessary statistics (e.g. counting hits in 
different branches and taxonomy levels, calculating F-measures, false negative rates etc.).  
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3. Results and discussion 
3.1. Discovering novel drug combinations 
In the past few decades, the number of novel marketed drugs has fallen much below the 
expectations despite the growing resources invested in this area [227-229]. Many biological 
pathways have rich regulatory loops, which can be utilized to compensate various perturbations. In 
cancer therapy, drugs acting on the HER2 (erb-b2 receptor tyrosine kinase 2) and EGFR (epidermal 
growth factor receptor) pathways have shown this type of drug evasion effects. Multitarget drugs 
or drug combinations have been proposed as a general strategy to circumvent this phenomenon 
[230, 231]; one of the reasons is that combinations often have less toxicity and higher therapeutic 
success [232]. The number of approved drug combinations is on the increase, even though most of 
them were established by experience and intuition [233, 234].  
About one-fourth of breast cancer patients express HER2 (human epidermal growth factor 
receptor-2), a transmembrane receptor tyrosine kinase of the epidermal growth factor receptor 
(EGFR) family. In HER2 positive patients, administration of trastuzumab, an anti-HER2 therapy, 
improved the progression free survival (PFS) and the overall survival (OS) [76]. It also enhanced 
survival as adjuvant therapy combined with chemotherapy [235] or as monotherapy after 
chemotherapy [236]. Since 2006, trastuzumab is also approved for use in adjuvant settings in HER2 
positive early breast cancer. Anti-HER2 therapy is highly successful: although high HER2 
expression was previously associated with worse survival, today HER2 positive patients have better 
prognosis as compared to women with HER2 negative disease [37].  
According to current NCCN guidelines (www.nccn.org), trastuzumab is given in 
combination with adjuvant chemotherapy only. Preferred regimes for chemotherapy with 
trastuzumab include Adriamycin, Cyclophosphamide, Paclitaxel, Docetaxel and Carboplatin. 
Numerous other agents are also included in protocols used for breast cancer patients including 
Methotrexate, Epirubicin, Fluorouracil and protocols containing combinations of these (FAC, CAF, 
CMF, EC, FEC, TAC, etc.). Thus, the combination of various agents into multi-agent protocols 
represents the backbone of the state of the art in systemic treatment for HER2 positive breast cancer. 
However, finding the most efficient combinations of these is not an easy task given the complexity 
of the underlying biological system. 
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Several experimental methods, even high-throughput methods [237], have been developed 
for measuring the efficiency of drug combinations, such as Bliss independence or Loewe additivity 
[238-240]. Wong et al. used a stochastic search algorithm [241], while Calzoari and associates 
employed sequential decoding algorithms for finding the best combinations [242]. Yang et al. used 
differential equations to find a perturbation pattern that can revert the system from disease state to 
a normal state [243]. Jin and associates employed a Petri net based model to microarray data in 
order to predict synergism of drug pairs [244]. A common feature of these computational methods 
is that they require a large number of experiments or deep knowledge of the kinetic parameters of 
the pathways even if the search space is small.  
Other studies used various combinations of data mining methods to integrate 
pharmacological and network data [245, 246]. Li and coworkers used the concept of network 
centrality and disease similarity to prioritize drug combinations [247]. Wu and associates used the 
microarray profile of the individual drugs for the predictions [245], and others applied the concept 
of synthetic lethality, and the available gene interaction data [248, 249]. Despite the countless 
attempts, there are still many challenges and open practical questions. In particular, finding suitable 
data representations and similarity measures is not a trivial problem because of the heterogeneity 
of information sources. Currently there are published data on a large number of drug combinations 
(six hundred in the DCDB and TTD databases as of March 2013), that refer to a variety of diseases 
and therapeutic targets. It is an open question whether or not the correlations and tendencies 
extracted from such heterogeneous datasets can be successfully applied to a specific problem, such 
as that of trastuzumab.  
Here I present a novel principle that is based on the assumption that perturbations generated 
by the pharmacological agents propagate through an interaction network to other targets that 
constitute what we call a propagation neighborhood. Overlaps of multiple propagation 
neighborhoods can then cause unexpected synergies at target genes that are not in the immediate 
vicinity of the original targets of the individual agents. I introduce a novel Target Overlap Score 
(TOS) that is based on the overlap of the propagation neighborhoods of the target proteins. I show 
that TOS is correlated with the known efficiency of beneficial and deleterious effects of drug 
combinations reported in the DCDB, TTD and Drugs.com databases. I also show that there is a 
correlation between TOS and the outcome of recent clinical trials where trastuzumab was used in 
combination with anthracycline- and taxane-based systemic chemotherapy in HER2-receptor 
positive breast cancer. 
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3.1.1. TOS: a network-based Target Overlap Score 
Drug molecules reach their therapeutic effects by acting on specific targets in the organism 
and activating or inhibiting the functions of their targets. Drug effects naturally do not end here, 
since drug targets are members of large interaction networks through which the perturbation can 
propagate. For instance, by inhibiting the action of a single molecule such as BRAF (B-Raf proto-
oncogene, serine/threonine kinase), the entire RAF/MEK/ERK (Raf-1 proto-oncogene, 
serine/threonine kinase, mitogen-activated protein kinase 1, mitogen-activated protein kinase 1) 
pathway will be tuned down, and as a consequence, collateral pathways including PI3K 
(phosphatidylinositol-4,5-bisphosphate 3-kinase) and RALA (v-ral simian leukemia viral oncogene 
homolog A (ras related)) will also be affected. In other words, a drug acting on a single target will 
concomitantly perturb a group of linked targets that is termed here as network neighborhood 
(Figure 3.1). 
 
Figure 3.1. The network interaction hypothesis 
The effect of two drugs (Drug1, Drug2) reaches their imminent targets first (arrows) and the effect will then 
propagate to their network neighborhoods (subnetworks) indicated in red and green, respectively. Targets in 
the overlap are affected by both drugs, and we suppose that drugs affecting a number of common targets will 
influence the effects of each other. The overlap is quantified as the proportion of jointly affected targets 
within all affected targets (in set theory terms: intercept divided by union). 
We hypothesize that two (or more) drugs can have an unexpected combined effect if their 
perturbation neighborhoods overlap. In order to capture this property, I define a Target Overlap 
Score (TOS) for two drugs as the number of jointly affected targets divided by the number of all 
affected targets. This simple definition has a few plausible consequences: i) TOS has a value 
between zero and 1.0, higher values indicating stronger joint effects. ii) As a mathematical 
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consequence, a drug will give TOS = 1.0 with itself. Note that even though a combination of two 
identical drugs does not occur in the clinical practice, it can cause a statistical bias in the 
comparisons so they have to be removed from the datasets used in the statistical comparison. iii) 
The concept of TOS can be generalized to more than two interacting drugs. Naturally, we have to 
decide in advance if, at one extreme, we want to consider genes perturbed by more than one agent 
in a drug combination only, or, at the other extreme, we consider just those genes that are perturbed 
by all of them. Here I used the former definition iv) The concept of TOS does not include any 
supposition about the beneficial or detrimental nature of combined drug effect. This is an important 
point since “drug interaction” in pharmacology denote negative, detrimental effect while the term 
“drug combinations” usually refer to beneficial, i.e. therapeutically useful combined effects. In 
principle, TOS can be correlated with both as I in fact show it in the next chapter. v) Finally, the 
definition of TOS is different from several other concepts related to traditional measures of drug 
interactions (antagonism, agonism, etc.) that mostly refer to effects of drugs on the activity of one 
target, such as a receptor. In contrast, TOS depends on the number of targets, and does not at present 
consider the magnitude (nor the positive or negative nature) of the effect.  
From the practical point of view, a subnetwork is a graph that can be described in terms of 
its nodes, links or its substructures (known subgraphs). For instance, a node-based description can 
be the number of nodes, shared by the two subnetworks (network neighborhoods). Since network 
neighborhoods can be of very different sizes, it is safer to normalize this value to the total number 
of affected nodes, which takes us to the well-known formula of the Jacquard or Tanimoto 
coefficient, which I use as a target overlap score (TOS). The TOS of two subnetworks 1net  and 
2net  is: 
 1 2
1 2
1 2( , )
net net
net net
V V
TOS net net
V V



  (29) 
This score can also be used for connections instead of nodes, and can be transformed into 
a weighted form. Namely, some algorithms assign weights to the nodes (edges). In such cases we 
can represent intersection and union by the sum of weights calculated for the participating nodes 
(edges) which then leads to the weighted variant of the overlap score. A probabilistic weighting is 
especially important, as it is generally applicable. In such a case, the weight assigned to a node can 
be the significance of the node (edge) derived from Monte-Carlo simulations; in this case, the 
overlap coefficient will have a statistical interpretation. 
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Here I defined network neighborhood as the set of genes that are significantly perturbed by 
a drug. This was determined by Monte Carlo simulation, by repeating the diffusion process 10,000 
times and determining the nodes (genes) whose activity changed at a chosen level significance 
(typically 0.05p  ). As a numerical measure for drug-drug interaction, I define the Target Overlap 
Score (TOS) as the Jaccard coefficient (similarity measure between sets) calculated between the 
neighborhoods significantly affected by a pair of drugs.  
Although several different propagation methods could be used for calculating the network 
neighborhood, I preferred the diffusion to PageRank, because it proved to be more robust in terms 
of changes in parameters, however, in some cases PageRank performed better. Furthermore, I tried 
to use as less parameters as possible to avoid the overfitting and to reduce the computation time 
needed for the optimization of the parameters.  
TOS is 1.00 for a pair of drugs affecting the same targets and 0.00 for agents that do not 
significantly affect any target in common.  
DCMS  , the perturbation of the i th drug iD  can be expressed as a vector: 
 ,( ) (0)
L t
DCM iS D e x
   , (30) 
where the j th entry of (0)x  nonzero if it is targeted by the drug: 
 1 if protein  is drug target(0) 0 otherwisej jx    (31) 
The j  th element of (D )DCM iS  measures the disruption effect of Di  on protein j . I used 
the parameters 0.1   and α 0.005  throughout this study. Then the network neighborhood or 
subnetwork of drug Di , iDnet  consists of the significantly perturbed network elements: 
  | , 0.05
i iD i i v
net v v V p     (32) 
Then the target overlap score is calculated as in equation 29. 
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Furthermore, this measure can be generalized to handle multiple drug combinations. For 
this purpose, one can determine the number of nodes that were significantly perturbed by at least 
two drugs, divided by the size of the affected subnetwork. 
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
   (33) 
This coefficient is zero if the neighborhoods do not overlap and 1.0 if they are identical. 
Identity is in fact a problem since a drug’s overlap with itself is not meaningful. To avoid this 
problem, the drugs participating in the analysis should be pre-screened and drugs with identical 
targets should be excluded from the analysis, either a priori, or by omitting their combination from 
the results. 
3.1.2. TOS is correlated with the strength of both beneficial and 
deleterious drug combinations 
For the evaluation, I chose a simple ranking test, i.e. I compared the TOS value calculated 
for known drug pairs with the TOS of randomly chosen drug pairs, and calculated an AUC value 
for the ranking using ROC analysis [1] as described in Section 1.6.5.  
It is noted that strong interactions are expected to give AUC values close to 1.0, while AUC 
values for randomly selected pairs are expected to be around ~ 0.5. In the present study, I used the 
STRING/STITCH interaction network, and the first question I asked was whether or not the 
evaluation system fulfils these fundamental criteria; for this purpose, I used the database of FDA-
approved drugs [106] and generated all possible binary combinations. Trivial interactions (drugs 
acting on the same target and drug pairs with identical or nearly identical chemical structures) as 
well as drug pairs known to have positive or negative effects were omitted from the analysis which 
left 733542 pairs. This evaluation gave an AUC value of 0.48 (Figure 3.2, left) which is very close 
to the random value of 0.5 This finding thus shows that, given the TOS algorithm applied to the 
STRING/STICTH network, the randomly chosen FDA-approved drug pairs indeed behave as 
random. I have to mention that the randomly selected drug pairs may have contained cases in which 
the interaction has not been discovered yet. A related question is that of drugs having identical 
targets. These should by definition give a TOS value of 1.00, and I found 271 such drug pairs. Also, 
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drugs having close to identical chemical structures are likely to affect similar targets. I found 179 
such drug pairs but only eight of these were common with the previous subset. The comparison 
shows that both subsets give high TOS values, which will statistically bias the comparison if 
included either in the positive or in the negative dataset of non-interacting drugs. Therefore, for the 
statistical evaluation described below, I left out these drug pairs from both datasets. 
 
Figure 3.2. Prediction performance on known drug interactions and combinations 
The prediction performance was measured on several different training sets (for details see Table 3.1), 
cancer-related drug-drug interactions and drug combinations. The prediction method is based on a simple 
measure, the Target Overlap Score (TOS). The prediction procedure was repeated 100 times with different 
negative sets, and then the average value was reported. The standard deviation of AUC values (not shown) 
are between 0.0001 and 0.006 for the different datasets. 
Next, I wanted to test whether or not TOS can help to identify the drug pairs that are 
empirically known to have a beneficial or detrimental effect. In pharmacology, two drugs are called 
"interacting" if their joint administration has a detrimental effect [250]. Drug pairs listed at 
http://drugs.com are classified into three groups according to the severity of the negative effects, 
such as major, moderate and minor. There are 10323 strongly, 92958 moderately and 17193 weakly 
interacting drugs in the database; however, in the selection I considered only cancer-related drug 
pairs, i.e. those, in which one of the agents was or was proposed to be used in treating cancer, which 
resulted in 817 strongly, 5700 moderately and 241 weakly interacting drugs from the database, 
denoted as sets A, B and C, respectively (Table 3.1). The results show that the interacting drug 
pairs show remarkably higher AUC values than the randomly selected drug pairs; moreover, these 
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values qualitatively follow the strength of the interaction (Figure 3.2). Namely, strongly interacting 
drug pairs show substantially higher AUC values than the moderately interacting ones, etc. 
Table 3.1. Datasets 
 Dataset Original size Size after filtering1 Data source 
Detrimental drug interactions2     
Severe A 1053 817 Drugs.com 
Moderate B 6857 5700 Drugs.com 
Minor C 273 241 Drugs.com 
Beneficial drug interactions3 
Total from DC4 D 429 293 DCDB, TTD 
Cancer-related5 E 55 33 DCDB, TTD 
1 I filtered the available drug pairs by leaving out the drug combinations where the components have exactly 
the same targets, or the components were structurally similar, as described above. Drugs with no available 
targets were also discarded; 2Taken from Drugs.com (November 11, 2013) as described below; 3Taken from 
the Drug Combination Database (March 8, 2012) and the Therapeutic Target Database (July 23, 2012); 4All 
approved drug combination were included; 5All approved drug combination that are used in cancer treatment. 
I also tested drug pairs that are known to have a beneficial effect when administered 
together. In pharmacology, the term “drug combinations” refers to drugs that are administered 
together because they have an empirically known beneficial therapeutic effect. Such therapeutically 
useful drug combinations are included in the Drug Combination Database (DCDB) [186] as well 
as in the Therapeutic Target Database TTD [223], along with the specific mechanism of their 
interaction. Using the same selection criteria, I selected 293 combinations (dataset D, Table 3.1). 
The results in Figure 3.2, right, show that therapeutic drug combinations yield AUC values 
substantially different from the random combinations. 
Next, I carried out the same comparisons for all drugs. In this case, the datasets were 
naturally larger. The results show the same general tendencies as seen in the case of all drug 
combinations (data not shown). Namely, i) the known interactions are substantially different from 
the combinations of non-interacting drugs; ii) the AUC values of minor, moderate and strong, 
detrimental interactions follow the correct order, i.e. the stronger the interactions the higher the 
AUC values; and iii) the values of beneficial, therapeutic combinations are also substantially 
different from the average and the AUC value of 0.91 in cancer-related combinations can be 
considered especially convincing iv) in Figure 3.2, the beneficial interactions show higher AUC 
values. We have no ready explanation for this phenomenon; however, we speculate that one of the 
reasons could be that therapeutic combinations are usually optimized via careful clinical studies. 
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3.1.3. TOS vs. GO and ATC codes 
 
Figure 3.3. Flow chart of the training and the prediction procedure 
The input is a list of candidate combinations (i.e. combinations selected for clinical trials) and the set of 
known combinations (i.e. previously approved cancer combinations). The first step is to compute the Target 
Overlap Score (TOS) and the drug interaction measures (GO, ATC) for all possible drug combinations. The 
database consists of the random generated drugs and of the components of the candidate and the known 
combinations. After the selection of the training sample (both the positive - known cancer combinations - 
and the negative one - random combinations) a logistic regression was trained using the previously computed 
TOS and similarity values. In the next step, the trained model is used for ranking a set of candidate 
combinations. The output is the ranked list of the drug combinations. 
Since TOS is conceptually different from other measures used to characterize drug 
interactions, one might expect that additional parameters successfully used in other studies can 
increase its ranking power. The most obvious way of boosting the performance of a classifier is to 
include more and more relevant knowledge on the drugs. Earlier studies suggest that the integration 
of disease similarity [247] or therapeutic information such as ATC code based similarity [221, 246, 
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251] as well as target similarity, such as GO annotations, could be useful as well [246, 249]. In 
order to test these possibilities, TOS was combined with GO or ATC based similarity metrics using 
logistic regression [252], a standard method in machine learning studies. The computational steps 
are summarized in Figure 3.4. I investigated various types of similarity measures defined in 
hierarchical networks (see Section1.6.6. for more details,) and I found that in the case of GO the 
simple cosine similarity, while in the case of ATC classification system the Resnik similarity 
produces the best results. Pairwise and ternary combinations of the three interaction measures 
(TOS, GO, ATC) were calculated by the logistic regression model [252]. Briefly, for a series 
1 2, , , nm m m  measures to be combined, the logistic regression model will calculate a combined 
measure M as 
 
 
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
, (34) 
where the i  regression coefficients are estimated by linear regression. 
The results in Figure 3.4 show that inclusion of new parameters did not substantially 
change the picture.  
The fact that the ranking power of TOS was not substantially improved when other 
parameters were added shows that TOS in itself captures a property that is well correlated with the 
empirically known interaction strength of various drug combinations. 
3.1.4. TOS shows correlation with the outcome of clinical trials 
In a clinical trial (also called „interventional study”), patients receive specific interventions 
according to a well-defined protocol [341]. In our case, trial data were collected from 
http://clinicaltrials.gov and consisted of studies in which combinations included trastuzumab either 
as an interaction partner or as a basis for comparison, and only those clinical scores were used that 
were collected according to RECIST [221]. The list of drugs tested in clinical trials included 
bevacizumab, capecitabine, carboplatin, cyclophosphamide, docetaxel, doxorubicin, epirubicin, 
fluorouracil, gemcitabine, ixabepilone, lapatinib, oxaliplatin, paclitaxel, pertuzumab, sunitinib.  
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First, I analyze the statistical dependence between the clinical outcomes and the TOS 
values calculated for the drug regimens used for the treatment. Several regimens included more 
than two agents, such as trastuzumab and three additional drugs, A, B and C. Spearman's rank 
correlation coefficient was used for quantifying the statistical dependence between the TOS score 
and the clinical outcome measures. The TOS scores of the drug combinations are in Table 3.2. 
.
 
Figure 3.4. Performance of combined predictors on different training sets 
The short titles TOS, TOS+ATC, TOS+GO or TOS+GO+ATC refer to the combination used. The curves 
represent the AUC value distribution (as a probability density function) obtained via a kernel density 
estimation (KDE) approach. The data were obtained by a 5-fold cross-validation procedure. Note that the 
distributions are quite similar to the TOS values (top left) which indicates that TOS effectively captures the 
drug combination phenomenon. 
The TOS score shows substantial correlation with the overall response (OR) (r=0.64; 
p=0.0028), Figure 3.5. Furthermore, the overall survival rate (OSR) and Confirmed Clinical 
Benefit (CCB) correlate well with TOS r=0.87; p=0.017 and r=0.84; p=0.0021).  
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Figure 3.5 Scatter plot of prediction scores and Overall Response 
The predicted scores are on the x axes, the clinical outcome, Overall Response (for the definition of outcome 
measures see the RECIST [35]) are on the y axes. Each data point corresponds to a multicomponent 
combination.  
 
Table 3.2. TOS scores of binary and multicomponent combinations 
Trastuzumab in binary 
combinations1 
TOS score2 
Trastuzumab in multiple 
combinations1 
TOS score2 
tra+doc 0.4138 tra+lap+5fu+cyc+epi+pac 0.7272 
tra+gem 0.4067 tra+5fu+cyc+epi+pac 0.6629 
tra+flu 0.3888 tra+doc+sun 0.6548 
tra+pac 0.3732 tra+per+doc 0.6133 
tra+dox 0.2509 tra+dox+doc 0.6058 
tra+epi 0.1105 tra+cap+doc 0.5108 
tra+cap 0.0845 tra+bev+doc 0.4707 
tra+cyc 0.0806 tra+gem+car 0.4170 
tra+ixa 0.0441 tra+ixa+car 0.0544 
tra+oxa 0.0155   
tra+car 0.0110   
1All combinations presented here were under clinical investigation as of 1st of January 2013. 
Components in the combinations were lapatinib (lap), fluorouracil (5fu), cyclophosphamid (cyc), 
epirubicin (epi), paclitaxel (pac), pertuzumab (per), docetaxel (doc), carboplatin (car), doxorubicin 
(dox), gemcitabine (gem), carboplatin (car), ixabepilone (ixa), oxaliplatin (oxa); 2The scores were 
computed using the generalized TOS. The larger the score the stronger the interaction. 
In conclusion, the data suggest that there is a significant correlation between the TOS 
scores and the outcome of clinical trials. 
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3.1.5. Discussion 
The TOS score is based on the intuitive expectation that drugs perturbing overlapping 
neighborhoods within a gene network will combine their effects either in the positive or in the 
negative sense, and that the strength of the combined effect is proportional to the ratio of jointly 
affected targets within all affected targets. The TOS measure will detect the overlap, but a high 
TOS will not tell if the variations are caused by positive or by negative synergies. Our tests showed 
that TOS is in a consistently good correlation with both, and that this correlation could not be 
substantially strengthened by including GO and ATC terms.  
A special advantage of TOS is the ability to rank potential drug combinations, so in addition 
to the best combination it can also show how the other potential combinations perform in a relative 
comparison. The examples in Table 3.2 list cases where trastuzumab was combined with a 
cytotoxic drug (binary combination), or was part of a larger regimen consisting of more drugs 
which were studied in clinical trials. The results illustrate our message for trastuzumab: the highest 
ranking scores were achieved by combinations containing docetaxel. In addition, the most potent 
single agent to be administered with trastuzumab was also docetaxel. A few agents reached low 
scores (cyclophosphamide, oxaliplatin, carboplatin, ixabepilone) when applied together with 
trastuzumab. Nevertheless, interestingly, some of these, like cyclophosphamide and epirubicin, 
have achieved much higher scores when applied in complex regimens, which underlies the complex 
nature of the therapeutic response. In this context, it is worth to note that we apparently cannot yet 
estimate whether TOS can help to predict progression free survival, which is one the most important 
measure of clinical outcomes. 
Even though the correlation of TOS with drug combination data is promising, its eventual 
use in predictive settings has important limitations. First, TOS relies on the protein-protein (or 
gene-gene) interaction data available in the databases. Though such data are accumulating at a 
growing pace, interactions missing from the current datasets may lead to erroneous predictions. An 
important property of the TOS score is that it can not by itself differentiate between positive and 
negative effects. Therefore, a high TOS value can mean either a positive, synergistic effect or a 
negative, deleterious drug interaction effect. As more information becomes available on the 
direction, strength and type (such as inhibition, activation, binding, etc.) of the interactions between 
the drug targets, some of the above limitations will be gradually eliminated. I also have to mention 
that completely or partly identical targets will by definition lead to high TOS values. While the 
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former are trivial, the second may be worth to evaluate. The distinction is not built into the TOS 
score itself, but these cases can be identified by straightforward computations. 
In addition, there is a conceptual difference between TOS and many of the other concepts 
of drug interactions. Namely, TOS does not limit drug-drug interactions or perturbations to 
identical drug targets or affected pathways. Instead, TOS captures a multitarget effect, and I think 
this is why the direction of the combined effect (i.e. beneficial vs. deleterious). can not be easily 
captured by the measure. Here a note on “beneficial” vs. “detrimental” effects is perhaps in place. 
Namely, many of the current, therapeutically useful drugs, including immunosuppressants or anti-
cancer drugs are effective because they are toxic to a restricted population of cells. In the context 
of a single biochemical network, such effects would be considered as deleterious, even though in 
the therapeutic sense they are beneficial to the entire organism. I think it is the task of experimental 
studies to decide whether a combination with outstanding TOS score is therapeutically useful. 
3.2. Prediction of cancer biomarkers by integrating text and data 
networks 
Predicting disease biomarkers consists in suggesting genes potentially associated with a 
disease. Traditionally, gene-disease associations are based on experimental data that have been 
validated by careful clinical studies. With the emergence of high-throughput techniques, it is 
possible to experimentally compare the behavior of all human genes in healthy and diseased states. 
However, the evaluation of such lists is not simple [253]. Computational methods of “gene 
prioritization” were developed for this purpose [254]. Most of the methods combine the new 
experimental data with a background database containing information on co-occurrence, functional 
annotations, protein-protein interactions, pathways, and gene expression. Briefly, we can view new 
experimental data as numerical scores assigned to genes, and the background database as a network 
of genes in which the links are defined by one of the methods mentioned above. In the process of 
gene prioritization, the experimental scores are updated using the gene network data and the genes 
are re-ranked based on the new scores. Updating of scores can be based on graph distance (shortest 
path), on a propagation algorithm such as the popular PageRank [255] or on diffusion methods 
[203], for example. The resulting methods differ in the kind of score updating methodology, the 
background database used, and most importantly, the size of the data they can handle. Relatively 
few methods can select genes from entire genomes or accept input data on all genes. For instance, 
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it is customary to restrict the scope of candidate genes to a small region of the chromosome using 
methods of linkage analysis or to use known disease genes as a training set. One of our goals is to 
use approaches analogous to the methods of gene prioritization in order to further increase the 
sensitivity of hypothesis generation. 
 Text mining has been successfully applied to finding various gene-disease associations 
[256], such as suggesting disease marker genes from MEDLINE records and ranking (prioritizing) 
genes based on biomedical literature [257]. Reviews of the earlier work are found in [258] and 
[259]. More recently, Hristovski and associates combined DNA microarray data and semantic 
relations extracted from MEDLINE, for generating novel hypotheses [260]. Frijters and colleagues 
also presented an application of their literature mining method in an open-ended retrieval of hidden 
relations for hypotheses in terms of gene-disease, drug-disease and drug-biological process 
associations [261]. 
3.2.1. Theory 
In the framework of knowledge discovery, a biomarker is a hypothesis generated from the 
evaluation of scientific literature. In the ideal case, hypothesis generation leads to a list of 
hypotheses that can be ranked according to various criteria. Generally speaking, a hypothesis is a 
previously unknown, indirect connection between term A (disease) and term C (cause). Knowledge 
discovery posits that such a hypothesis is validated if both the cause and the disease are related to 
the same set of intermediate concepts, which is the basis of the well-known ABC model of 
Swanson. Hypothesis generation is a different task as it seeks to identify novel hypotheses rather 
than confirming one. The RaJoLink model of Petrič et al [262] approaches this problem by looking 
at “rare terms”, i.e. concepts sporadically appearing in the literature that may be linked to common, 
hitherto unknown causes. In an ideal case, the causes emerging in this manner can be ranked by 
importance [3]. The same principle can be used to select potential biomarkers. In this case, the 
starting phenomenon is a disease (i.e. the same as before) but the terms we are looking at are the 
names or symbols of genes or pathways. The approach presented in this section relies on the 
supposition that genes (pathways) sporadically mentioned in the scientific literature my point to a 
set of genes (pathways) that is the cause of the disease, so mutations in these genes (pathways) may 
then be used as biomarkers for the disease. The goal of this section is to show how a common data 
network of scientific abstracts and protein-protein interactions can be used to automate this process. 
Namely, in the data network described in the previous sections diseases are linked to genes (as well 
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as drugs). In this section, a new type of link, “co-occurrence” was added, denoting that a disease 
and a gene are mentioned in the same scientific publication. On such an enhanced network, the 
problem of hypothesis generation can be defined as a neighborhood-overlap problem as shown in 
Figure 3.6. In this section, ovarian cancer was used as the test case. 
 
Figure 3.6. The principle of biomarker prediction using terms rarely associated with 
cancer and a set of validated genes 
A “hypothesis” is a gene worth to be experimentally tested. Such a gene (network node) is expected to rarely 
- but appreciably – associate with cancer terms in scientific papers (light red area), but has no, or no strong 
evidence for cancer involvement (light green area). In the picture, such genes are located within the 
intersection of the light-shaded areas, and the ones of interest are identified by ranking them according to a 
suitable criterion. The principle of biomarker prediction using terms rarely associated with cancer and a set 
of validated genes. 
3.2.2. Constructing a data-network with molecular and literature-based 
links 
The benchmark datasets were designed to test whether or not a method could efficiently 
predict that a gene plays a certain role, which was then experimentally confirmed later. For this 
test, a corpus of abstracts is needed being published before a certain biological role was confirmed. 
I chose ovarian cancer as the model disease and used a recently published list of 37 ovarian cancer 
biomarker (OC biomarkers) genes [263] (Table 3.3) as test cases. I then wanted to determine if the 
relationship between these genes and ovarian cancer could have been predicted on the basis of 
literature published beforehand. In order to have a sufficient number of genes in the analysis, I 
selected the year 2007 as a separating line. A total of 10 OC biomarkers have been proposed after 
this date. 
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OC biomarker abstracts were selected using the search phrase: (biomarker OR biomarkers 
OR marker OR markers) AND (“cancer of ovary" OR "ovary cancer" OR "cancer of the ovary" 
OR "ovarian cancer" OR "malignant neoplasm of ovary" OR "malignant ovarian neoplasm" OR 
"malignant tumor of ovary" OR "malignant tumor of the ovary" OR "malignant neoplasm of the 
ovary" OR "malignant ovarian tumor" OR "malignant tumor of ovary" OR "ovarian malignancy" 
OR "ovarian carcinoma"). This search resulted in 4,878 abstracts published before the year 2007. 
This set was defined as the OC biomarker test corpus. Separately, 26,979 abstracts about the known 
OC biomarker genes [263] (Table 3.3) published up until May 14th 2012 were obtained and these 
formed the OC biomarker prediction corpus. HGNC gene symbols, names and their synonyms were 
used (downloaded on December 23rd 2011). Such HGNC nomenclature was then applied to the 
terms that were automatically extracted from collections of MEDLINE abstracts. 
Table 3.3. List of ovarian cancer biomarker genes published before May 2012 
 Symbol Gene  Symbol Gene  Symbol Gene 
1 CA125 CA 125 [264-267] 14 P16 p16 [268, 269] 26 BIRC5 Survivin [270] 
2 KRT19 Cytokeratin 19 [271, 272] 15 CDKN1A p21 [273-275] 27 TERT hTERT [276] 
3 KLK6 Kallikrein 6 [277] 16 CDKN1B p27 [278-281] 28 EGFR ERBB1 [282, 283] 
4 KLK10 Kallikrein 10 [284] 17 RB1 pRB [285, 286] 29 ERBB2 ERBB2 [287] 
5 IL6 Interleukin-6 [288] 18 E2F1 E2F1 [289] 30 MET c-Met [290] 
6 IL7 Interleukin-7 [291] 19 E2F2 E2F2 [292] 31 MMP2 MMP-2 [293] 
7 IFNG γ-interferon [294] 20 E2F4 E2F4 [292] 32 MMP9 MMP-9 [295] 
8 FAS sFas [296, 297] 21 TP53 p53 [298, 299] 33 MMP14 MT1-MMP [300] 
9 VEGFR VEGFR [301] 22 TP73 p73 [302] 34 SERPINB5 Maspin [303] 
10 CCND1 Cyclin D1 [273, 304] 23 BAX Bax [305, 306] 35 BRCA1 BRCA1 [307] 
11 CCND3 Cyclin D3 [308] 24 BCL2L1 Bcl-xl [309] 36 ERCC1 ERCC1 [310] 
12 CCNE Cyclin E [311-314] 25 BIRC2 cIAP [315] 37 WFDC2 
(HE4) 
Epididymis 
protein 4 [316-
318] 
13 P15 p15 [319]      
3.2.3. Principle of evaluation 
From the mathematical point of view, genes selected by text mining analysis can be viewed 
either as an unranked set of gene names or as a ranked list wherein genes are characterized by their 
names as well as by a numerical score. I used two kinds of methods for re-ranking the genes selected 
by the enhanced RaJoLink rare-term algorithm described here: a) standard gene prioritization 
methods available via gene prioritization web servers (ToppGene and Endeavour) [320, 321] and 
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b) propagation-based methods that were implemented on the STRING database [322], as briefly 
described in Section 1.6.1 and 1.6.3. 
More specifically, the PageRank iteration was initiated from the known disease-associated 
genes, biomarkers, thus the vector pr  is defined as: 
 1
if protein i is a known OC biomarker
0 otherwise
i
Mpr


 


, (35) 
where M  is the number of validated biomarkers. 
Similarly, the diffusion process was initiated from known biomarker genes: 
 
1 if protein i is a known OC biomarker(0) 0 otherwiseix   (36) 
3.2.4. Testing the methods on the rediscovery of known OC biomarker 
genes 
The goal is to establish whether the genes that have been proposed as OC biomarkers after 
2007 could have been predicted on the basis of prior literature evidence and knowledge. Genes 
suggested as biomarkers are those that co-occurred with the term “marker” or “biomarker” in 
MEDLINE abstracts. MEDLINE abstracts, MeSH and HUGO terms published before 2007 and 
standard propagation algorithms (PageRank or diffusion kernel methods [203, 255]) were used for 
re-ranking the results, using the network of the STRING database, release version 6.3 (in use from 
December 12, 2005 to January 15, 2007). In the re-ranking step I could not use the gene-
prioritization servers as the current servers contain information entered after 2007.  
Out of the 37 ovarian cancer genes listed in Table 3.3, 27 are mentioned together with 
“marker” or “biomarker” in MEDLINE articles published before 2007. The remaining 10 genes 
(the target genes) are: BCL2L1, CCND3, E2F1, E2F2, E2F4, ERCC1, IL7, MET, MMP9, WFDC2. 
Six genes were identified with the enhanced RaJoLink method. For five of these six genes, the 
ranks could be substantially improved by propagation/re-ranking (Table 3.4). 
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Table 3.4. List rediscovery of genes suggested as OC biomarkers 
Gene 
symbol 
Gene 
Year when first 
mentioned as 
ovarian cancer 
prognostic 
marker 
Rank 
Original 
RaJoLink 
New 
RaJoLink 
New 
RaJoLink 
+ 
PageRank 
New 
RaJoLink 
+ Personal 
Diffusion 
BCL2L1 Bcl-xl 2007 NA 337 5 10 
CCND3 Cyclin D3 2007 NA 165 43 31 
E2F1 E2F1 2008 NA NA NA NA 
E2F2 E2F2 2007 69 140 36 3 
E2F4 E2F4 2007 39 16 NA NA 
ERCC1 ERCC1 2007 NA NA NA NA 
IL7 Interleukin 7 2007 54 297 82 80 
MET c-Met 2007 NA NA NA NA 
MMP9 MMP-9 2007 44 86 22 49 
WFDC2 Epididymis protein 4 2009 NA NA NA NA 
3.2.5. Prediction of new OC biomarkers 
I wanted to establish if any putative gene biomarkers might exist for ovarian cancer on the 
basis of currently available published knowledge. To achieve this, an experiment similar to the 
previous one was completed where i) the data input was the ovarian cancer prediction corpus which 
includes abstracts about the known OC biomarker genes [263] (Table 3.3) published up until May 
14, 2012 and current versions of STRING, MeSH, HUGO nomenclature data, and ii) the 
propagation step was carried out with the standard propagation algorithms (PageRank or diffusion 
kernel methods [203, 255]), and also with the gene prioritization servers ToppGene and Endeavour 
[320, 321]. It was apparent that a number of well-known cancer-related genes appear in the top of 
these lists.  
For a better overview, I compared the top of the lists and picked 10 genes that ranked highly 
in most of the rankings (Table 3.5). These include RUNX2, SOCS3, BCL6, PAX6, DAPK1, 
SMARCB1, RAF1, E2F6, P18INK4C (CDKN2C), and PAX5. These are all cancer-related genes 
that have not previously been proposed as OC biomarkers and have not been mentioned in literature 
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sources together with ovarian cancer. These may represent genetic markers upon which hypotheses 
can be formulated in relation to ovarian cancer. 
Table 3.5. Predicted OC biomarker genes 
3.2.6. Discussion 
Here I applied an open knowledge discovery method that generates hypotheses that are not 
known in advance. The methodology suggests potential disease-gene associations based on text 
databases (in our case MEDLINE), MeSH terms, and the HUGO nomenclature. It was found that 
unequivocal matching to gene symbols is a very important factor, and that re-ranking text-based 
predictions either by standard propagation algorithms (PageRank, Diffusion Ranking) applied to 
the STRING network, or by gene-prioritization servers available on the web can improve the 
efficiency of text-mining searches.  
The searches revealed a number of genes that were previously not associated with 
progression and prognosis of ovarian cancer in MEDLINE abstracts. The RUNX2 transcription 
factor is a putative tumor suppressor gene localized at chromosome 1p36, a region showing 
frequent loss of heterozygosity events in colon, gastric, breast and ovarian cancers [327]. RUNX2 
has also been associated with prostate [328], lung [329], breast cancer [330], osteosarcoma [331], 
thyroid tumors [332]. Several other studies demonstrated a link between RUNX2 and the hormonal 
system in prostate [333] and breast cancer [334]. All these data suggest a possible contribution of 
RUNX2 to proliferation via enhancing the growth factor effects of sexual hormones. The potential 
Genes predicted as ovarian cancer biomarkers Validation 
after May, 
2012 Gene symbol Gene 
RUNX2 Runt-related transcription factor 2 [323, 324] 
SOCS3 Suppressor of cytokine signaling 3 NA 
BCL6 B-cell lymphoma 6 protein [325, 326] 
PAX6 Paired box protein Pax-6 NA 
DAPK1 Death-associated protein kinase 1 NA 
SMARCB1 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily B member 1 
NA 
RAF1 RAF proto-oncogene serine/threonine protein kinase NA 
E2F6 Transcription factor E2F6 NA 
P18INK4C 
(CDKN2C) 
Cyclin-dependent kinase 4 inhibitor C NA 
PAX5 Paired box protein Pax-5 NA 
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of the gene in this association is supported by the prognostic power of hormone receptors in ovarian 
cancer [335]. In 2012 it was also confirmed that RUNX2 is associated with advanced tumor 
progression in epithelial OC [324]. In addition, the inhibition of RUNX2 lead to significant 
decrease of cell proliferation [336]. 
BCL6 (B-cell CLL/lymphoma 6) is another transcription factor found to be frequently 
mutated in diffuse large-cell lymphoma. The gene was related not only to lymphomas [337] and 
leukemias [338], but also to progression to breast [339], gastric [340] and lung cancer [341]. 
Interestingly, both BCL6 [342] and RUNX2 [343] are influenced by prolactin secretion. Wang et 
al. showed that BCL6 is a negative prognostic factor in ovarian cancer [325] and the inhibition of 
BCL6 along with NACC1 [326] reduced the invasion capabilities of cancer cells. 
The tumor suppressor DAPK1 (death-associated protein kinase 1) is one of the key 
regulators of the extrinsic apoptotic pathway [344]. Genetic variation of DAPK1 is associated with 
survival in breast cancer [345]. The methylation status of DAPK1 contributed to stratifying colon 
cancer patients into subgroups with different prognosis [346]. The correlation between apoptotic 
machinery and DAPK expression has just recently been validated in the ovarian cancer cell line 
OVCAR-3 [347]. Taken together, DAPK1 might be a potent prognostic marker for predicting 
apoptotic activity and tumor progression in various cancer types including ovarian cancer.  
Of the remaining top-ten candidate genes, PAX6, E2F6, SMARCB1 and PAX5 also 
regulate gene transcription, while SOCS3, RAF1 and P18INK4C play a role in signal transduction 
pathways. In summary, the identified genes modulate key elements of molecular pathways of 
tumorigenesis and have already been associated with the progression in various malignancies. 
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3.3. Inference on hierarchical graphs: fast and sensitive alignment 
of microbial whole metagenome sequencing reads 
Simply put, annotation of metagenomics sequencing reads consists of two essential parts: 
i) mapping reads to taxa and determining the taxon (strain, species, genus, etc.) composition, and 
ii) mapping reads to functions and determining the functional repertoire (functional composition) 
of the community. These two tasks can be carried out by the same computational step. Namely, a 
read is mapped to a specific location within a genome. The genome name is mapped to the taxon 
so we have the answer for i). The location within the genome is mapped to a function so we have 
the answer for ii). The problem is that the mappings are part of a large and complex data network 
represented in a data-warehouse, which may not guarantee a sufficiently fast access to the required 
information. The solution is to construct a small, dedicated database that only contains the required 
data. Importantly, both taxonomy and function are defined to hierarchical graphs, so by using a 
database of appropriate format we can reduce the problem to fast tree-operations. For this, we need 
to design and benchmark an efficient algorithm, as described in the subsequent chapters.  
The work described in this chapter is a close collaboration with Lőrinc S. Pongor 
(Semmelweis University) and Roberto Vera (Pázmány University) [348]. The Taxoner algorithm 
was developed by Lőrinc, the database necessary for fast execution was developed by Roberto. My 
own contribution was to design the conceptual scheme for the underlying data-network, to develop 
test cases for the testing and the statistical evaluation. My work also included the selection and 
implementation of programs used for comparison [82, 85, 88, 349] . 
3.3.1. Taxoner algorithm 
The idea behind Taxoner comes from a technical problem. Running fast aligners such as 
Bowtie2 on a large number of microbial genomes is prohibitively time consuming, since – at least 
in principle – each of the small genomes has to be indexed separately. However, if we concatenate 
the small bacterial original genomes into larger units, i.e. concatenated FASTA files that are termed 
“artificial chromosomes”, the problem becomes more manageable. In such an artificial 
chromosome, a genome is a segment that is annotated by various identifiers including taxonomic 
name and GI identifier. As such the number of reads matching a particular genome can be counted 
at various taxonomic levels which corresponds to the well-known principle of taxonomic binning 
[350]. The only prerequisite is to know the starting and endpoints of the genomes and/or other 
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segments incorporated into the “artificial chromosome”, which is solved by pre-calculated index 
files.  
Importantly, this process is analogous to the mapping of reads to an annotated genome 
wherein the segments – i.e. the genes – are named according to such schemes as COG [351, 352], 
GO [353], etc. Namely, in both cases, a read is mapped to a large sequence consisting of annotated 
segments, and the segments are named according to various ontologies. As a consequence, this 
algorithm can be used both for taxon identification and for function prediction based on NGS 
datasets. It must be highlighted that mapping of counts to ontologies, sometimes also referred to as 
“ontology binning”, is a problem known in other fields of medical informatics as well [354]. Further 
analogies can be found in protein sequence similarity searching wherein BLAST hits (HSPs) are 
mapped to domains annotated within proteins [355-359]. 
 
Figure 3.7. The Taxoner algorithm 
In the first step, the short reads were mapped to the microbial genomes. Next, the alignments were 
preprocessed and only those hits were mapped to the taxonomy tree that were above a certain threshold. In 
the classification or the binning step, the read was assigned to the lowest common ancestor of the taxa it hit. 
The algorithm has two computational phases. Firstly, as a preprocessing, a database of an 
arbitrary number of species is segmented into partitions (“artificial chromosomes”), then the 
Bowtie2-build program of the Bowtie2 package is used to index them [360]. Pre-built indices are 
available on the project site (http://code.google.com/p/taxoner). Phase II is the alignment itself for 
which the Bowtie2 was used. The lowest common ancestor algorithm provided the base for the 
identification of the taxa (Figure 3.7Hiba! A hivatkozási forrás nem található.). The output, which 
is a summary of the taxa and the alignments, is provided in SAMtools format.  
DOI:10.15774/PPKE.ITK.2016.008
70 
Furthermore, it is also possible to process the read alignments and the output with other 
programs such as MEGAN [85]. 
Table 3.6. Benchmark datasets 
Dataset ID  Sequencing 
platform and  
number of 
spots; average 
read length 
Taxon Note 
A SRR292150 454 GS 20 
(183203;110.31) 
Staphylococcus aureus 
subsp. aureus 
USA300_TCH959 
(NCBI taxon id: 
450394) 
Randomly selected1, 
Supplementary file2 
B ERR236069 Ion Torrent PGM 
(1338465;262.05) 
Staphylococcus aureus 
(NCBI taxon id: 1280) 
Randomly selected1, 
Supplementary file2 
C SRR017390  Illumina 
Genome 
Analyzer II 
(26391487;76) 
Staphylococcus aureus 
subsp. aureus 67-331 
(NCBI taxon id: 
585131) 
Randomly selected1, 
Supplementary file2 
     
D DRR000184 Illumina Genome 
Analyzer II 
(7631281;50) 
Bacillus anthracis 
BA104 (NCBI taxon id: 
Not Available) 
Randomly selected1, 
Supplementary file2 
E DRR000184 Illumina Genome 
Analyzer II 
(7631281;50) 
Bacillus anthracis 
BA104 (NCBI taxon id: 
Not Available) 
Whole run3 
F AE017225 NA(104574;99.9
9) 
Bacillus anthracis str. 
Sterne (NCBI taxon id: 
260799) 
Full genome sampling4 
, supplementary file2 
G SRX055380 Illumina Genome 
Analyzer II 
(6562065; 75.00) 
HMP Mock Community 
even sample 
Whole genome 
sequencing 
1Random selected datasets were produced by a Python script that uniformly sampled the read collection 
without replacement. The sample size was 100000. 2Supplementary files are deposited at 
http://pongor.itk.ppke.hu/taxoner/examples/ 3The whole run was analyzed. 4The genome was sampled with 
overlapping reads. The read length was uniformly 100bp and the overlap between the adjacent reads was 
50bp. 
3.3.2. Execution times 
The evaluation of Taxoner’s performance was carried out by comparing it to MetaPhlAn 
[88], BLAST (legacy blast) [361], and BLAST+ (dc-megablast) [362]. In the last two cases, the 
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MEGAN taxon assignment program was used [83, 85]. The former was chosen for the speed and 
accuracy it shows in the estimation of taxon composition, and the latter one for its outstanding 
performance in alignment. However, comparing the performance of the above-mentioned programs 
is not trivial for various reasons; for instance, MetaPhlAn has its own database with 367 million 
nucleotides including only bacteria, and it reads to this taxon-marker database. The other two, on 
the other hand, can run on more complex databases, like NCBI NT, which contains 52 000 million 
nucleotides of all species, or on a bacterial subset as well. These factors also impact the speed and 
the accuracy of the results. As a conclusion, it is clear that the size of the database, the number of 
threads used for the calculation, and the length and the number of the reads to be evaluated define 
the actual alignment times for the three programs. The typical results of the comparisons are shown 
in Table 3.7. As can be seen, Taxoner’s performance is in between the running time of Blast and 
MetaPhlAn, meaning Taxoner being fast enough to be performed on an ordinary desktop PC or a 
laptop, although the indexing of the database requires more time. 
Table 3.7. Average execution times of alignments  
 Taxoner1 MEGABLAST2 MetaPhlAn3 
nt database4 nt database4 unique marker 
db5 
1 thread6 2446 sec 37.6h 7 sec 
12 threads6 1866 sec 9.4h 6 sec 
1Running times include the read classifications; 2Read classifications are not included; 3Running 
times include the read classifications; 4The nt database size is 1507MB (as of 11/07/2013); 5The 
database size is 367MB; the measurement was carried out on an Intel(R) Xeon(R) CPU E5-2640 
processor, the query reads: Dataset A, Table 3.6. 
3.3.3. Compatibility with various sequencing platforms 
The development of sequencing technologies has given rise to a number of sequencing 
platforms in recent years. The performance of read aligners often varies on the basis of reads 
produced by the various sequencing platforms. I compared the performance of aligner programs on 
read datasets selected from Staphylococcus aureus sequencing data (dataset A, B and C from Table 
3.6 with results shown in Table 3.8). BLAST aligners had the highest alignment rate, which is not 
surprising since BLAST is a sensitive local aligner. MetaPhlAn had the lowest alignment rates, 
which is again expected, since MetaPhlAn only aligns reads to a unique subset of the bacterial 
database (i.e. clade-specific markers). In general, all aligners had the best performance on the 454 
dataset, since the 454 reads are longer and thus easier to analyze. All programs performed well at 
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genus level. An important aspect of metagenome analysis is the identification of taxa at the lowest 
possible taxonomic levels, such as species or strains. At the species level, Taxoner showed the best 
performance with the exception of 454 reads where BLAST performed better. On the other hand, 
none of the programs identified strains very reliably (strain level identification is not even available 
with MetaPhlAn). The discrepancies may however be caused by the fact that the sequencing data 
used in this comparison were partly taken form uncharacterized strains (dataset B, Ion Torrent data) 
or from a strain not in the database of Staphylococcus aureus subsp. aureus 67-331 (NCBI taxon 
id: 585131, dataset C, Table 3.6, Illumina data). 
Table 3.8. Read assignment for Staphylococcus aureus genome sequencing data 
    Roche 454 (Dataset A)1 Ion Torrent (Dataset B)1 Illumina (Dataset C)1 
 Level: Genus Species Strain Genus Species Strain Genus Species Strain 
Taxoner Total 93692 93692 93692 37175 37175 37175 27531 27531 27531 
Positive 93189 92728 62 36482 35919 0 26023 17019 0 
Negative 4 43 875 28 126 17174 29 121 1213 
FNR %2 0.004 0.046 0.934 0.075 0.339 46.198 0.105 0.440 4.406 
Meta-
PhlAn 
Total 8525 8525 8525 2522 2522 2522 1692 1692 1692 
Positive 8209 8063 N/A3 2402 2399 0 1650 1613 N/A 
Negative 0  N/A 43 36 0 2 28 N/A 
FNR % 0.000 0.493 N/A 1.705 1.427 N/A 0.118 1.655 N/A 
BLAST
ALL + 
MEGAN 
Total 86752 86752 86752 68696 68696 68696 45721 45721 45721 
Positive 83718 82951 156 65264 63801 0 41189 27375 0 
Negative 25 29 53 114 125 5310 408 441 3094 
FNR % 0.029 0.033 0.061 0.166 0.182 7.730 0.892 0.965 6.767 
DC-
MEGAB
LAST + 
MEGAN 
Total 84211 84211 84211 64858 64858 64858 48677 48677 48677 
Positive 81000 80035 140 61662 60199 0 44161 29466 0 
Negative 48 68 131 94 128 3052 81 180 3421 
FNR % 0.057 0.081 0.156 0.145 0.197 4.706 0.166 0.370 7.028 
1100,000 random selected reads from experimental data. 2False Negative Rate. 3Not available. 
3.3.4. Detecting an unknown anthrax strain 
As different bacterial strains may have quite similar sequences, it is essential to know 
whether the database contains the given genome or not. This question is also motivated by the fact 
that the microorganisms detected in environmental samples are mainly unknown strains. Being an 
unknown strain here means not having the genome or draft genome deposited in any well-known 
sequence database. To test how the algorithms handle the above-mentioned case, the detection 
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probability of two Bacillus anthracis strains was compared to each other. I chose Sterne strain as 
the “known” strain (NCBI taxon id: 260799), which is used for vaccination. The dataset contained 
100bp long overlapping segments (“artificial reads”) of its own genome, offset by 50bp (dataset 
F). A Japanese isolate (B. anthracis strain BA104; NCBI taxon id: Not Available) represented the 
unknown strain being not included in the database at the time of the analysis. The dataset contained 
7.7 million Illumina reads (dataset E). It is not surprising that the proportion of false negative results 
(number of misclassified reads) was higher for the unknown strain as shown in Figure 3.8. 
 
Figure 3.8. Analysis of anthracis strain not included in the database 
The read classifications predicted by MetaPhlAn and Taxoner on an artificial dataset (Table 3.6, dataset F) 
made from a known anthrax strain and an unknown anthrax strain (Table 3.6, dataset E) was compared. Here, 
the percentages of classified reads on species level are reported. Both sample consists of exactly one bacterial 
species. The dataset F contains 104574 synthetic reads, while the Dataset F (Table 3.6) 7,379,118 reads. 
As expected, Taxoner could perfectly detect the synthetic reads that were generated without 
introducing any error from a genome being included in the database. It is surprising, however, that 
MetaPhlAn identifies, even in the synthetic reads, a considerable amount of species that are not 
present in the samples. It must be noted that B. anthracis is a member of the B. cereus group. This 
includes three related species: B. cereus, B. thuringiensis and B. anthracis. These three are highly 
related, which is also supported by the fact that about 75% of the synthetic reads generated from 
the Sterne strain are 100% identical in them (data not shown). The difference between the three 
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programs is that MetaPhlAn assigns these reads to the Bacillus genus, while the other two assign 
them to the B. cereus group. This illustrates that both the database and the taxonomy definitions of 
the given programs deeply influence the species % reported by them.  
3.3.5. Detection of very low abundance reads 
When it comes to detecting pathogens, one of the most important questions is the sensitivity 
of the test, which can be estimated from the number of reads safely detected by the analysis. I tried 
to estimate this value by randomly selecting a fixed number of reads from an experimental anthrax 
dataset (dataset E) in conjunction with the NT dataset (Figure 3.9). Number of reads necessary on 
average to detect an unknown species at various taxonomy levels. Error bars indicate standard 
deviation of the mean, calculated from 400 repetitions. 
 MetaPhlAn was used in conjunction with its own dataset. The analysis was repeated for 
each set of data. It is apparent that at species level, Taxoner/Bowtie2 performed better than BLAST 
or MetaPhlAn. At genus and higher levels, all methods performed well even though it was apparent 
that MetaPhlAn needed one-two orders of magnitude more reads to complete the identification than 
the other programs. Taxoner and BLAST were able to detect a genus essentially from one read 
while MetaPhlAn needed 200-350 reads on average for the identification. Species level 
identification was apparently more difficult for all programs, with Taxoner and BLAST needing 10 
or 15 reads for the identification.  
3.3.6. Analyzing metagenomic datasets 
Analysis of metagenomic data from NGS reads has two goals: a) establishing the presence 
or absence of taxa at the lowest possible taxonomic level and if possible at species/strain level, and 
b) estimating the relative amounts of taxa.  
I also investigated on the MOCK community samples published by the Human 
Microbiome Project. These are synthetic microbiomes consisting of 21 known microbial species 
with known composition that were used to develop sequencing protocol. There are two different 
composition types available: one is uniform, i.e. each strain concentration is the same, the other is 
staggered, where the concentrations are not constant. Each community was sequenced using 
various approaches and sequencing platforms (16S, WGS-Illumina).  
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Figure 3.9. Detection of low abundance strains 
Number of reads necessary on average to detect an unknown species at various taxonomy levels. Error bars 
indicate standard deviation of the mean, calculated from 400 repetitions. 
Table 3.9. Identification of taxa in even MOCK community 
1The analysis was run on dataset G, Table 3.6; 2True positive; 3False positive; 4False negative; 
5The F-measure was calculated as 2TP/(2TP+FP+FN); 6Positive taxa predicted by Taxoner are 
those that received at least 1000 hits. 
0
1
10
100
1000
species genus family
DC-MEGABLAST BLASTALL Taxoner MetaPhlAn
Number of reads necessary for positive identification
(for a "novel" anthrax species not included in the database)
  strain species genus family 
Number of positives (taxa present)1 22 22 19 18 
Taxoner6 
TP2 14 20 17 17 
FP3 7 2 2 1 
FN4 8 0 0 0 
F-measure5 0.65 0.95 0.94 0.97 
MetaPhlAn 
TP NA 21 18 18 
FP NA 1 1 0 
FN NA 7 5 6 
F-measure NA 0.84 0.86 0.86 
WGSQUICKR 
TP 1 9 13 13 
FP 20 13 6 5 
FN 79 67 45 29 
F-measure 0.02 0.18 0.34 0.43 
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The analysis revealed that Taxoner is able to detect a taxon in a complex community (Table 
3.6, dataset G) even in strain level (Table 3.9); however, MetaPhlAn (and WGSQUICKR) is not. 
The classification accuracy of Taxoner and MetaPhlAn is comparable in this task. In order to 
improve the accuracy in Taxoner a minimum threshold was applied for the number of reads needed 
for reporting a taxa as positive, omitting the filtering step leaded to high number of false positive 
identifications. MetaPhlAn and other programs, such as Megan, also use similar strategies. I also 
investigated a recently published tool, WGSQUICKER [349], that uses compressed sensing 
technique applied on genome composition information for detecting the taxa presenting in a 
sample. However, the approach is extremely fast, the number of false positive and negative 
identifications is large. 
3.3.7. Discussion 
Here I presented a novel approach for the analysis of whole genome shotgun metagenomics 
results. Taxoner utilizes a Burrow-Wheeler Transform (BWT) based fast aligner and a 
comprehensive sequence database along with a comprehensive taxonomy tree in order to interpret 
and efficiently analyze the massive sequencing data. The improved indexing strategies made it 
possible to evaluate metagenomics datasets in a single PC, without compromising the classification 
performance. Taxoner performed better in speed and accuracy than BLAST-based tools. 
Detecting unknown strains is often a problematic task for aligners. It is proved that strains 
of the same species may have high variability in their genome. As a consequence, the analysis of, 
for example, soil bacteria may involve the detection of strains being largely unknown to the current 
databases. It follows from this that Taxoner using a comprehensive database has an advantage 
compared to other approaches using marker databases. It can be explained by the fact that new 
strains may not contain the unique sequences that are included in the marker database. The above-
described problem is rather important because strain level identification is needed for the detection 
of hazardous pathogens. Only a few programs include this feature (strain level identification), and 
Taxoner is one of them. The fact that its sensitivity is much better than that of the pipelines based 
on BLAST is a result of the program using Bowtie2 instead of BLAST. These results implicate that 
combining fast alignment techniques with comprehensive databases can end up in a proper 
alternative for sensitive analysis of metagenomic samples. Lastly, it is shown that pathogen 
identification is a basically different task from metagenome analysis thus requiring specific 
treatment. There are three features in Taxoner that help pathogen identification: i) the feature of 
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removing the reads originated from the host organism (by specifying a host genome);ii) an output 
in a format that is compatible with Megan and can be submitted to it, thus one can manually identify 
pathogens, and iii) the possibility of relying on dedicated databases. For example, after creating a 
specialized database one can directly use this for the analysis (or, naturally, download a standard 
database from our repository). 
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4. Conclusions and new scientific results 
In this work I investigated how different graph models can help in various bioinformatics 
problems. My research covered the following areas: i) finding novel drug combinations, ii) finding 
novel, unexpected biomarkers from literature, and iii) improving the classification performance of 
metagenomics reads. 
In the first case the data network consists of protein-protein associations and drug-protein 
associations, and I used other types of data networks as well, like hierarchical data networks (GO 
and ATC classification system). In the second application the basic data network was built from 
literature information and protein-protein associations. Finally, in the third case, taxonomy tree and 
Clusters of Orthologous Groups (EggNOG) were used. Both are hierarchical networks; the former 
one more or less represents the phylogeny, the latter provides a resource for functional annotations 
for microorganisms. 
However, there is a basic difference between the motivation of the above approaches: in 
the last case network-based methods are used to help interpreting our experimental data by reducing 
noise and finding reliable results by revealing the possible enriched functions in the diverse bacteria 
cocktail; while in the first two cases the goal is to find novel, unexpected relationships between 
various objects by applying the concept of network neighborhood on different data networks. 
In the second application the network neighborhood was selected by using a static approach 
as described in Section 1.6 and 3.2. The genes being in the static neighborhood are considered to 
be related to the disease and represent a large body of new hypotheses. However, these predictions 
are noisy, but other data networks, such as protein-protein interactions, could be used efficiently to 
improve the prediction accuracy in terms of ranking. The task of reordering interconnected 
elements is a very common task in networks and the traditional searching algorithms such as 
PageRank and diffusion processes proved to be useful. 
In spite of the similar goal, namely to reveal unexpected relationships between different 
objects, in the first case the network neighborhood was constructed not in a static, but in a dynamic 
way using also the diffusion processes as described in Section 1.6 and 3.1.1.  
Despite of the different motivations, I attempted to address the problem with the help of 
hierarchical networks both in the first and the third case. It proves to be useful in annotation 
processes (i.e. in metagenomic problems) and in finding similarities, but does not help with ranking 
drug combinations.  
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4.1. Network neighborhood analysis – revealing unexpected 
relationships 
The idea underlying network neighborhood analysis is seemingly simple: a concept, such 
as a molecule or a pathway represented in a biological database, is not a single object but a 
subnetwork of interrelated concepts and relationships. From this, it trivially follows that 
subnetworks can overlap with each other so we can significantly broaden the scope of associations 
between concepts and extend the analysis of hidden, implicit links, which is the essence of new 
discoveries. What is not trivial is how to design a network in which associations will be useful; in 
other terms, we can answer practical questions with the help of it. The suggestion put forward in 
the first two subsections of Section 3 is that we construct a data network dedicated for a given 
purpose. Namely, if we want to query associations between diseases, drugs and drug targets, we 
construct a network consisting from these items, by combining, say drug databases (STITCH [111], 
DrugBank [107], TTD [223], DCDB [113]), interaction databases (STRING [4], IntAct [137]), 
disease databases (OMIM [363]), and various resources such as ontologies [89, 90] and manually 
curated datasets. Alternatively, if we want associations based on text mining, we include a network 
composed of our useful terms (say, diseases, target genes) and text-mining based links between 
them. Such dedicated data networks take some expertise to construct, but the time of network 
construction and analysis are not prohibitively long. What is questionable, of course, is how good 
our data are. Here we have no guarantees for success, just the hope that the body of databases and 
the number of new database types will continue to increase as fast as it does today, and that novel 
types of integration methodologies will emerge. Currently, a bottleneck in the construction of data 
networks is data heterogeneity, namely the concepts are not uniformly defined across the various 
databases we want to integrate in a network. With these caveats in mind, these approaches should 
be considered as pilot studies into two seemingly unrelated directions, the prioritization of drug 
combinations, and prediction of potential biomarkers.  
Since hypothesis generation based on genomic data is a key problem in life sciences today, 
this approach can also be used in other fields. The limitations of this approach follow by the 
probabilistic nature of the answers. For instance, I considered the prediction of a drug combination 
successful if the successful combination was in the toplist of say 10 best hits. Since the number of 
potential drug candidates is very high, such a ranking can be considered a partial success, since one 
can narrow down the experiments to a relatively small number of cases. On the other hand, we 
expect that semantic pruning of the network may improve the efficiency of predictions in the future. 
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Namely, one may design useful rules regarding which links of the networks should be omitted from 
the analysis. In such a manner the size and complexity of the network could be decreased so more 
sophisticated algorithms could be used for the analysis. In view of the efforts invested into 
biomedical ontologies, we can trust that this development will broaden the scope of the network 
analysis technique proposed here.  
4.1.1. Prediction of efficient drug combinations 
In the first part of my thesis I showed that molecular interaction data can successfully 
predict known combinations of chemotherapeutic agents used to treat breast cancer. Here the 
prediction is a ranking, in which the efficient combinations are expected to be in the top of the list. 
The performance, namely how good a ranking is, was characterized with the AUC value. This score 
is 1 if the ranking is perfect (i.e. all efficient combination ranked at the top), 0.5 if it is random. 
Drug - drug interactions are often considered as harmful “negative combinations”, since they 
increase the risk of side effects and may cause “overdose”. On the other hand, drug combinations 
are considered to be desirable (positive) since they can be efficiently used in the treatment of 
complex diseases. We could show that a simple network overlap measure is well correlated with 
the intensity of positive and negative drug interactions as well as with clinical data. 
 
Thesis group I. 
Related publications of the author: [J1][J3][C1] 
THESIS I.1. I have developed a novel drug combination prediction method based on the 
assumption that a perturbation generated by multiple drugs propagates through an interaction 
network and the drugs may have unexpected effect on targets not directly targeted by either of them 
(Figure 3.1). I introduced a new index, the so-called Target Overlap Score (TOS), to capture this 
phenomenon. The score quantifies the potential amplification effect as the overlap between the 
affected subnetworks. The score is computed as the Jacquard or Tanimoto coefficient between the 
sets of nodes in the subnetworks (for details see Section 3.1.1). 
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THESIS I.2. I have showed that using the TOS score it is possible to distinguish both the 
drug-drug interactions and the drug combinations from random combinations. I also presented 
that this measure is correlated with the known effects of beneficial and deleterious drug 
combinations taken from the DCDB, TTD and Drugs.com databases (Figure 3.2). 
THESIS I.3. I have also investigated that combining two frequently used drug-drug 
similarity measures with TOS - namely the functional similarity of drugs computed based on their 
imminent targets, and their therapeutic similarity quantified by using the anatomical therapeutic 
chemical (ATC) classification system - does not improve the classification performance. 
THESIS I.4. I have demonstrated the utility of TOS by correlating the score to the outcome 
of recent clinical trials evaluating trastuzumab, an effective anticancer agent used in combination 
with anthracycline- and taxane-based systemic chemotherapy in HER2-receptor (erb-b2 receptor 
tyrosine kinase 2) positive breast cancer. 
4.1.2. Prediction of cancer biomarkers by integrating text and data 
networks 
In biomarker prediction I showed that novel biomarkers can be prioritized using a network 
built from text mining data as well as ovary cancer data. In particular, I found that new biomarkers 
discovered in a given period of time are correlated with gene names sporadically emerging in the 
oncological literature of the previous years.  
Since many current medical hypotheses are formulated in terms of molecular entities and 
molecular mechanisms, here the methodology is extended to proteins and genes using a 
standardized vocabulary as well as a gene/protein network model. The proposed enhanced 
RaJoLink rare-term model combines text mining and gene prioritization approaches. Its utility is 
illustrated by finding known, as well as potential gene-disease associations in ovarian cancer using 
MEDLINE abstracts and the STRING database. 
Thesis group II. 
Related publications of the author: [J1][J6] 
THESIS II.1. I have improved the sensitivity of the RaJoLink rare term based algorithm by 
using network analysis algorithm such as personalized diffusion ranking and PageRank with Prior 
on the STRING protein-protein association network. 
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THESIS II.2. Based on the enhanced prediction I have proposed 10 novel genes - RUNX2, 
SOCS3, BCL6, PAX6, DAPK1, SMARCB1, RAF1, E2F6, P18INK4C (CDKN2C), and PAX5 - that 
are likely to be related to the disease and at the time had not been described as such. Since 2012, 
two of them (RUNX2, BCL6) have been confirmed. 
4.2. Fast and sensitive characterization of microbial studies 
Next generation sequencing (NGS) of metagenomic samples is becoming a standard 
approach to detect individual species or pathogenic strains of microorganisms. Computer programs 
used in the NGS community have to balance between speed and sensitivity and as a result, species 
or strain level identification is often inaccurate and low abundance pathogens can sometimes be 
missed. In metagenome analysis I showed that a dedicated database, consisting of taxonomic and 
gene classification data mapped to whole genome sequences, can be successfully used to quickly 
identify both species composition and functional repertoire in metagenomic samples. When used 
in conjunction with fast sequence alignment methods, Taxoner data network provides a more 
accurate identification of species compositions than standard marker-based methodologies such as 
MetaPhlAn. 
In the recent years various sequencing platforms have been developed. I compared the 
classification performance of Taxoner, MetaPhlAn [88] and BLAST [361, 362] combined with 
Megan [83, 85] on whole genome sequencing datasets of Staphylococcus aureus produced by 
Roche 454, Ion Torrent and Illumina. The low false negative rates implicate that Taxoner is almost 
as reliable as BLAST+Megan, however, it requires much less computational power and time. 
I analyzed the MOCK dataset representing 22 microbial strains and species in equal 
amounts provided by the Human Microbiome Project for validation purposes. The dataset consists 
of 6.5 Illumina short-reads. Taxoner was capable of confidently detecting most of the taxa (14/22) 
even in strain level. 
In the application to pathogen detection the sensitivity of the analysis is a crucial question. 
The sensitivity was measured as the number of reads necessary for detecting a certain species. After 
randomly sampling an experimental anthrax dataset the analysis revealed that Taxoner could 
confidently identify the anthrax from 10 reads, while MetaPhlAn needed 200-350 reads. 
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Sensitive detection of microorganisms with unknown sequence is a crucial question as 
well, since the majority of them are still unknown. In order to assess the classification performance 
on unknown species (their genome sequence is missing from the database) I analyzed an 
experimental anthrax dataset (B. anthracis strain BA104; NCBI taxon id: Not Available). Taxoner 
classified the majority of reads (96.50%) as Bacillus anthracis, s small portion 1.2% was classified 
as other species from the Bacillus genus. 
 
Thesis group III. 
Related publications of the author: [J5] 
THESIS III.1. I have demonstrated that by using hierarchical networks such as taxonomy 
along with fast aligners, i.e. bowtie2, the evaluation of high-throughput sequencing data is feasible 
in a reasonable time with good classification accuracy. The algorithm assigns the individual reads 
to the common ancestor of the taxa having its genome hit by the short read (Hiba! A hivatkozási 
forrás nem található.).  
THESIS III.2. I have illustrated the applicability of the Taxoner principles on whole 
genome shotgun sequencing of known or unknown pathogens (Staphylococcus aureus, Bacillus 
anthracis). The results suggested that the performance of Taxoner is as good as the state-of-the-
art BLAST based methods, while it is faster by two orders of magnitude. Finally, it is also 
compatible with various sequencing platforms. 
THESIS III.3. I have proved that using the Taxoner principles it is possible to characterize 
the microbial communities at the lowest taxonomic level, even in species or strain level.  
THESIS III.4. Taxoner is sensitive and capable of identifying taxa being present only in 
small abundance; furthermore, it needs two orders of magnitude less reads to complete the 
identification than MetaPhlAn. In addition, the method is applicable in cases where the genome 
sequence of the studied microbe is unknown. 
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